$NFEC Corporation Announces Business Visit in India

SHENYANG, China, June 8, 2017  — NF Energy Saving Corporation (NFEC) (“NF Energy” or the Company), a leading energy saving service solutions provider for China’s power, petrochemical, coal, metallurgy, construction and municipal infrastructure development industries, announced that a business visit in India was completed recently.

In order to expand the international market based on the “one belt and one way” policy issued by the Chinese government, representatives sent by NF Energy and Liaoning Nengfa Tiefa Import&Export Co. Ltd. visited the related companies in Hyderabad, India so as to look for the potential partners, such as discussed with VISHWA company on the disposal project in Hyderabad, India .

The Companies discussed our product’s quality and characteristics based on energy conservation and emission reduction to reduce costs, as well as introducing our current market situation. Meanwhile, they also mentioned some projects cooperated with other countries, such as Italy, Russia and Malaysia etc. According to our presentation, many India Companies were very interested in our products, and the cooperation in some projects are still under way. It is expected that the amount of our total orders will be more than $3 million this year in Indian market.

In recent years, the requirement of valves are rapidly increased in China and India as the representatives of the developing countries which became the largest valve markets in the world. The Indian industrial valve market is expected to reach more than $1 billion in demand in 2017.

About NF Energy Saving Corporation

NF Energy Saving Corporation (NASDAQ:NFEC) is a China-based provider of integrated energy conservation solutions utilizing energy-saving equipment, technical services and energy management re-engineering project operations to provide energy saving services to clients. The Company’s customers are mainly concentrated in the electrical generation (large-scale thermal power generation, hydroelectric power, and nuclear power), water supply, and heat supply industries. The majority of revenues are from energy efficient flow control solutions including equipment and energy efficiency project services. For more information, visit http://www.nfenergy.com.

Safe Harbor Statement

The statements contained herein that are not historical facts are considered “forward-looking statements.” Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” or “anticipates” or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, statements regarding the efficacy of investment in research and development are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the effect of political, economic, and market conditions and geopolitical events; legislative and regulatory changes that affect our business; the availability of funds and working capital; the actions and initiatives of current and potential competitors; investor sentiment; and our reputation. We do not undertake any responsibility to publicly release any revisions to these forward-looking statements to take into account events or circumstances that occur after the date of this report. Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events, which may cause actual results to differ from those expressed or implied by any forward-looking statements. The factors discussed herein are expressed from time to time in our filings with the Securities and Exchange Commission available at http://www.sec.gov.

Contact:

Andy Gao
Phone Number: 0086-24-25609775
Email: info@nfenergy.com

$HYGS Announces Extension of Outside Date for US$21 Million Private Placement

MISSISSAUGA, Ontario, June 08, 2017 — Hydrogenics Corporation (NASDAQ:HYGS) (TSX:HYG) (the “Company” or “Hydrogenics”), a leading developer and manufacturer of hydrogen generation and hydrogen-based fuel cell modules, today announced that, further to its press release of April 28, 2017 relating to the proposed issuance of 2,682,742 common shares of Hydrogenics to Fuzhou Bonded Zone Hejili Equity Investment Limited Partnership (“Hejili”) on a private placement basis for gross proceeds to Hydrogenics of US$21,000,000 (the “Private Placement”), the Company has exercised its option under the subscription agreement with Hejili to extend the outside date to close the Private Placement by 15 days to June 27, 2017. The extension provides additional time to obtain all applicable stock exchange approvals and Chinese regulatory approvals.

The Private Placement is subject to certain closing conditions, including the receipt of final stock exchange approvals and all applicable Chinese regulatory approvals. The outside date, after which either the Company or Hejili can terminate the subscription agreement if closing has not occurred by such date, is now June 27, 2017, subject to a further 15 day extension at the option of the Company.  There can be no assurance that the Chinese regulatory approvals will be obtained before the outside date, as extended, or at all.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

The securities will not be and have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold into the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities Act), absent registration or an exemption from registration requirements. The securities have not been and will not be qualified for sale by way of a prospectus under Canadian securities laws.

About Hydrogenics
Hydrogenics Corporation (www.hydrogenics.com) is a world leader in engineering and building the technologies required to enable the acceleration of a global power shift. Headquartered in Mississauga, Ontario, Hydrogenics provides hydrogen generation, energy storage and hydrogen power modules to its customers and partners around the world. Hydrogenics has manufacturing sites in Germany, Belgium and Canada and service centers in Russia, Europe, the US and Canada.

About Hejili
Headquartered in Fuzhou, Fujian province, China, Fuzhou Bonded Zone Hejili Equity Investment Limited Partnership is a limited partnership founded in 2016.  Hejili’s partners include Fujian Snowman Co., Ltd. (SZSE:002639), Ningbo Meishan Bonded Zone Mingde Investment Partnership, Ningbo Meishan Bonded Zone Mingde Investment Partnership, and Snow-Hydro Industrial Investment Management Ltd.

Forward-looking Statements
This release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995, and under applicable Canadian securities law. These statements are based on management’s current expectations and actual results may differ from these forward-looking statements due to numerous factors. Readers should not place undue reliance on Hydrogenics’ forward-looking statements. Investors are encouraged to review the section captioned “Risk Factors” in Hydrogenics’ regulatory filings with the Canadian securities regulatory authorities and the US Securities and Exchange Commission for a more complete discussion of factors that could affect Hydrogenics’ future performance. Furthermore, the forward-looking statements contained herein are made as of the date of this release, and Hydrogenics undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release, unless otherwise required by law. The forward-looking statements contained in this release are expressly qualified by this.

Investor Contacts:
Bob Motz, Chief Financial Officer
(905) 361-3660
investors@hydrogenics.com

Chris Witty
Hydrogenics Investor Relations
(646) 438-9385
cwitty@darrowir.com

$ABIL Announces Receipt of Nasdaq Letter

TEL AVIV, Israel, June 8, 2017  — Ability Inc. (NASDAQ: ABIL) (the “Company”), a leading provider of innovative tactical communications intelligence solutions, today announced that on June 6, 2017 it received notification from the Listing Qualifications Department of The Nasdaq Stock Market (the “Staff”) that the Company is not in compliance with the minimum bid price requirement set forth in Nasdaq’s Listing Rule 5550(a)(2).

Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s ordinary shares for the 30 consecutive business days ended June 5, 2017, the Company no longer meets the minimum bid price requirement. The deficiency notification does not result in the immediate delisting of the Company’s ordinary shares from the Nasdaq Capital Market.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has an initial grace period of 180 calendar days, or until December 4, 2017 (the “Compliance Period”), to regain compliance with the minimum bid price requirement. If, at any time during the Compliance Period, the bid price for the Company’s ordinary shares closes at $1.00 or more for a minimum of 10 consecutive business days, the Staff will provide notification to the Company that it complies with the minimum bid price requirement, unless the Staff exercises its discretion to extend this 10 day period requirement pursuant to Nasdaq Listing Rule 5810(c)(3)(F).

If the Company does not regain compliance with the minimum bid price requirement during the Compliance Period, the Company may be afforded an additional 180 calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, except for the minimum bid price requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the minimum bid price deficiency.

If the Company does not regain compliance with the minimum bid price requirement during the Compliance Period and is not eligible for an additional compliance period at that time, the Staff will provide notification to the Company that its ordinary shares may be delisted. The Company would then be entitled to appeal the Staff’s determination to a Nasdaq Listing Qualifications Panel and request a hearing. There can be no assurance that, if the Company does appeal the delisting determination by the Staff to the Nasdaq Listing Qualifications Panel, such appeal would be successful.

At present, the Company intends to monitor the closing bid price of its ordinary shares and may, if appropriate, consider available options to regain compliance with the minimum bid price requirement, which could include effecting a reverse stock split. However, there can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement.

About Ability Inc.

Ability Inc. is the sole owner of Ability Computer & Software Industries Ltd. (“Ability”) and Ability Security Systems Ltd.

Headquartered in Tel Aviv, Israel, Ability was founded in 1994. Ability provides advanced interception, geolocation and cyber intelligence tools used by security and intelligence agencies, military forces, law enforcement and homeland security agencies worldwide. Ability has sold to governments and government agencies in over 50 countries. Ability offers a broad range of lawful interception, decryption, cyber and geolocation solutions for cellular and satellite communication, including ULIN, or Ultimate Interceptor, which to our knowledge, is the first-to-market SaaS strategic interception system with voice and geolocation capabilities without geographic limitation. State-of-the-art technology underpins Ability’s scalable offerings, which can be tactical-and-portable, or strategic-and-fixed, depending on its customers’ needs. Additional information regarding Ability may be found at http://www.interceptors.com.

Caution Regarding Forward-Looking Statements

This press release contains “forward-looking statements.” Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Investor Relations Contacts:

MS-IR LLC
Miri Segal
Tel: 917-607-8654
msegal@ms-ir.com

$CERS Provides Update on U.S. Platelet Additive Solution (PAS) Supply

This follows a decision by the FDA to review a recent submission by Fresenius Kabi as a Changes Being Effected in 30 Days (CBE-30) supplement, which allows ongoing distribution of the product during the review period. The CBE-30 was necessary to address some changes in raw materials used by the manufacturer of the PAS container.

For Cerus’ customers who produce INTERCEPT platelets on the Amicus collection platform, Fresenius Kabi platelet additive solution is a key component of the manufacturing process.

“We are cautiously optimistic that a future supply shortage for our customers has been mitigated by the FDA decision,” noted William ‘Obi’ Greenman, Cerus’ president and CEO. “Our goal is to continue to support our customers and help minimize potential supply disruptions pending a final FDA approval of the change to the PAS container,” Mr. Greenman continued.

In the U.S., INTERCEPT platelets may be produced in a mixture of PAS and plasma (65% PAS and 35% plasma) on platelets collected on the Amicus apheresis platform, or in 100% plasma on platelets collected on the Trima Accel apheresis platform. An individual blood center may have both collection platforms available, or may standardize their production on one platform.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See www.cerus.com for information about Cerus.

INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation. Amicus is a trademark of Fresenius Kabi. Trima Accel is a trademark of Terumo BCT, Incorporated.

Forward-Looking Statements

Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus’ products, prospects and expected results, including statements concerning Cerus’ 2017 annual product revenue guidance and its expectations for U.S. revenue contribution in 2017 and the timing thereof; and Cerus’ expectations regarding Fresenius Kabi’s ability to supply PAS. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation: risks associated with the commercialization and market acceptance of, and customer demand for, the INTERCEPT Blood System, including the risks that Cerus may not meet its adjusted revenue guidance for 2017 and/or realize meaningful revenue contributions from U.S. customers in 2017 or otherwise, particularly since Cerus cannot guarantee the volume or timing of commercial purchases, if any, that its U.S. customers may make under Cerus’ commercial agreements with these customers; risks associated with Cerus’ lack of commercialization experience in the United States and its ability to develop and maintain an effective and qualified U.S.-based commercial organization, as well as the resulting uncertainty of its ability to achieve market acceptance of and otherwise successfully commercialize the INTERCEPT Blood System for platelets and plasma in the United States, including as a result of licensure requirements that must be satisfied by U.S. customers prior to their engaging in interstate transport of blood components processed using the INTERCEPT Blood System; risks related to Fresenius Kabi’s efforts to assure an uninterrupted supply of PAS; risks related to how any future supply disruption could affect INTERCEPT’s acceptance in the marketplace; risks related to how any future supply disruption might affect current commercial contracts; risks related to Cerus’ ability to commercialize the INTERCEPT Blood System in the United States without infringing on the intellectual property rights of others; risks related to Cerus’ ability to demonstrate to the transfusion medicine community and other health care constituencies that pathogen reduction and the INTERCEPT Blood System is safe, effective and economical; the uncertain and time-consuming development and regulatory process, including the risks (a) that Cerus may be unable to comply with the FDA’s post-approval requirements for the INTERCEPT platelet and plasma systems, including by successfully completing required post-approval studies, which could result in a loss of U.S. marketing approval for the INTERCEPT platelet and/or plasma systems, (b) related to Cerus’ ability to expand the label claims and product configurations for the INTERCEPT platelet and plasma systems in the United States, which will require additional regulatory approvals and (c) that Cerus may be unable to file for CE Mark approval of the red blood cell system in Europe in the anticipated timeframe or at all, and even if filed, Cerus may be unable to obtain CE Mark approval, or any other regulatory approvals, of the red blood cell system in a timely manner or at all; risks related to adverse market and economic conditions, including continued or more severe adverse fluctuations in foreign exchange rates and/or weakening economic conditions in the markets where Cerus sells its products; Cerus’ reliance on third parties to market, sell, distribute and maintain its products; Cerus’ ability to maintain an effective manufacturing supply chain, including the ability of its manufacturers to comply with extensive FDA and foreign regulatory agency requirements; the impact of legislative or regulatory healthcare reforms that may make it more difficult and costly for Cerus to produce, market and distribute its products; risks related to future opportunities and plans, including the uncertainty of future revenues and other financial performance and results, as well as other risks detailed in Cerus’ filings with the Securities and Exchange Commission, including Cerus’ Annual Report on Form 10-Q for the quarter ended March 31, 2017, filed with the SEC on May 4, 2017. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

$SNES ContraPest Receives State Registration for Florida

FLAGSTAFF, Ariz., June 7, 2017  — SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, announced today that ContraPest has been registered in Florida, bringing the total state registrations to forty-nine.

Dr. Loretta P. Mayer, Chair, CEO and co-founder of SenesTech, said, “We continue to add key customers, in targeted segments and geographies. Many of these key accounts are on a ‘try it and then buy it,’ basis, with small quantities needed at the outset, but with potentially exponential growth when the account transitions to the expanded ‘buy it’ stage.”

Dr. Mayer continued, “We are particularly pleased with the registration of ContraPest in Florida, one of our tropical life zones. As Florida moves into the summer months, the warm weather creates an optimal environment for an increase in rodent reproduction, and we see strong potential for ContraPest in that market.”

About SenesTech

SenesTech has developed an innovative technology for managing animal pest populations through fertility control as opposed to a lethal approach.

The Company’s first fertility control product, ContraPest^®, is marketed for use in controlling rat infestations. ContraPest’s novel technology and approach targets the reproductive capabilities of both sexes, inducing egg loss in female rodents and impairing sperm development in males. Using proprietary bait stations, ContraPest is dispensed in a highly palatable liquid formulation that promotes sustained consumption by rodent communities. ContraPest is designed, formulated and dispensed to be safe for handlers and non-target species such as wildlife, livestock and pets, in a biodegradable product. In contrast, the historical approach to managing rodent pest populations, rodenticides, carries a high risk of environmental contamination and the poisoning of non-target animals, pets and children.

We believe our non-lethal approach, targeting reproduction, is more humane, less harmful to the environment, and more effective in providing a sustainable solution to pest infestations than traditional lethal pest management methods. There is currently no other non-lethal fertility control product approved by the Food and Drug Administration (FDA), or the Environmental Protection Agency (EPA), for the management of rodent populations.  We believe ContraPest^® will establish a new paradigm in rodent control, resulting in improved performance in rodent control over rodenticides, without the negative environmental effects of rodenticides.  For more information visit the SenesTech website at www.senestech.com.

Safe Harbor Statement
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in our filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACT:

Investor: Robert Blum, Joe Dorame, Joe Diaz, Lytham Partners, LLC, 602-889-9700, senestech@lythampartners.com

Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc, 928-779-4143

$VSTM to Present Long-Term Follow-Up Data from the DYNAMO™ Study

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced long-term follow-up data from the DYNAMO™ study, which met its primary endpoint of Overall Response Rate (ORR; p=0.0001) at the final analysis, will be presented at the 14th International Conference on Malignant Lymphoma (ICML), being held June 14-17, 2017 in Lugano, Switzerland. DYNAMO is a Phase 2 clinical study evaluating the safety and efficacy of duvelisib monotherapy in patients with indolent non-Hodgkin lymphoma (iNHL) who were refractory to both rituximab and chemotherapy or radioimmunotherapy. Duvelisib is an investigational dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma that has demonstrated clinical activity as an oral monotherapy in multiple hematologic cancers, including chronic lymphocytic leukemia (CLL), iNHL, and T-cell lymphoma.

The long-term follow-up results from the study will be highlighted in an oral presentation titled, “DYNAMO: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Double-Refractory Indolent Non-Hodgkin Lymphoma,” given by Pier Luigi Zinzani, MD, PhD, University of Bologna Institute of Hematology, on Thursday, June 15, 2017 at 15:40 CET (9:40 ET) in Room A, Cinema Corso and Aula Magna (Lugano University).

“The data we are presenting at ICML help fill in the clinical picture for those patients who receive duvelisib over a longer period,” noted Dr. Zinzani. “Not only did duvelisib monotherapy continue to show robust and durable responses in double-refractory iNHL, but longer-term exposure to duvelisib did not reveal any unexpected safety findings. These results suggest duvelisib has favorable benefit-risk in double-refractory iNHL, and may provide an important new treatment option for a population in need of new targeted therapies.”

Patients enrolled in DYNAMO all had double-refractory iNHL and a median of 3 prior anticancer regimens. Of the 129 patients enrolled, 61 responded (1 complete response [CR], 60 partial responses [PR]), for an overall response rate (ORR) of 47%, as determined by an independent review committee. The ORR in each of the three disease subgroups included: 43% in follicular lymphoma (n=83); 68% in small lymphocytic lymphoma (n=28); and 33% in marginal zone lymphoma (n=18). Responses generally occurred shortly after the start of treatment (median 2 months). Notably, 88% of all patients treated with duvelisib had a reduction in the size of their target lymph nodes. Overall, median duration of response was 10 months, median progression-free survival was 9 months, and median overall survival was 27.8 months.

With additional follow-up (median 18 months), the safety profile of duvelisib monotherapy remains consistent with what has been previously reported in iNHL and other hematologic malignancies. The most common Grade ≥ 3 adverse events were hematologic in nature (neutropenia 30%, thrombocytopenia 15%, anemia 14%). Diarrhea was the most frequently reported nonhematologic adverse event (47%; 15% Grade ≥ 3). As expected in a heavily pretreated and refractory patient population, infections of all types and grades were observed (56%). Pneumonitis and colitis, events previously described with duvelisib, remained relatively uncommon (9% and 5%, respectively). Treatment discontinuations attributed to the most common adverse events were infrequent, suggesting that these events were generally manageable.

“The clinical activity and durability of responses observed in the DYNAMO study seen across a range of highly-refractory disease subtypes, together with the well-characterized and manageable safety profile, highlight the potential of this drug in lymphoid malignancies,” said Hagop Youssoufian, MSc, MD, Head of Hematology and Oncology Development at Verastem. “What I find really encouraging, is that we saw these results in patients refractory to both rituximab and chemotherapy, a specific population with unmet medical need.”

Following conclusion of Dr. Zinzani’s presentation, a copy of the presentation will be available here.

More About the Phase 2 DYNAMO™ Study

DYNAMO™ is a Phase 2, single-arm study, which evaluated the efficacy and safety of duvelisib 25 mg twice daily as monotherapy in 129 iNHL patients, including follicular lymphoma (n=83), small lymphocytic lymphoma (n=28), and marginal zone lymphoma (n=18) whose disease has progressed and are refractory to rituximab and to either chemotherapy or radioimmunotherapy. The primary endpoint of the study was ORR as assessed by an independent review committee.

About the Tumor Microenvironment

The tumor microenvironment encompasses multiple tumor and non-tumor cell populations and an extracellular matrix that support cancer cell survival. This includes immunosuppressive regulatory T-cells, myeloid-derived suppressor cells, tumor-associated macrophages, cancer-associated fibroblasts, and extracellular matrix proteins that can hamper the entry and therapeutic benefit of cytotoxic T-cells and anti-cancer drugs. In addition to targeting the proliferative and survival signaling of cancer cells, Verastem’s product candidates, including duvelisib and defactinib, also target the tumor microenvironment to potentially improve response to therapy.

About Duvelisib

Duvelisib is an investigational, dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, two enzymes known to help support the growth and survival of malignant B-cells and T-cells. PI3K signaling may lead to the proliferation of malignant B-cells and is thought to play a role in the formation and maintenance of the supportive tumor microenvironment.^1,2,3 Duvelisib is currently being evaluated in late- and mid-stage clinical trials, including DUO™, a randomized, Phase 3 monotherapy study in patients with relapsed or refractory CLL,⁴ and DYNAMO™, a single-arm, Phase 2 monotherapy study in patients with refractory iNHL that achieved its primary endpoint of ORR.⁵ Duvelisib is also being evaluated for the treatment of hematologic malignancies through investigator-sponsored studies, including T-cell lymphoma.⁶ Information about duvelisib clinical trials can be found on www.clinicaltrials.gov.

About Verastem, Inc.

Verastem, Inc. (NASDAQ: VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 2 study in iNHL and is currently being evaluated in a Phase 3 clinical trial in patients with CLL. In addition, Verastem is developing the FAK inhibitor defactinib, which is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer, and mesothelioma. Verastem’s product candidates seek to treat cancer by modulating the local tumor microenvironment, enhancing anti-tumor immunity, and reducing cancer stem cells. For more information, please visit www.verastem.com.

Verastem, Inc. forward-looking statements notice:

This press release includes forward-looking statements about Verastem’s strategy, future plans and prospects, including statements regarding the development and activity of Verastem’s investigational product candidates, including duvelisib and defactinib, and Verastem’s PI3K and FAK programs generally, the structure of our planned and pending clinical trials and the timeline and indications for clinical development, and our rights to develop or commercialize our product candidates. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include the risks that the preclinical testing of Verastem’s product candidates and preliminary or interim data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that data may not be available when expected; that enrollment of clinical trials may take longer than expected; that our product candidates will cause unexpected safety events or result in an unmanageable safety profile as compared to their level of efficacy; that duvelisib will be ineffective at treating patients with lymphoid malignancies; that Verastem will be unable to successfully initiate or complete the clinical development of its product candidates; that the development of Verastem’s product candidates will take longer or cost more than planned; that Verastem may not have sufficient cash to fund its contemplated operations; that Verastem or Infinity Pharmaceuticals, Inc. will fail to fully perform under the duvelisib license agreement; that Verastem will not pursue or submit regulatory filings for its product candidates; and that Verastem’s product candidates will not receive regulatory approval, become commercially successful products, or result in new treatment options being offered to patients. Other risks and uncertainties include those identified under the heading “Risk Factors” in Verastem’s Annual Report on Form 10-K for the year ended December 31, 2016 and in any subsequent filings with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Verastem’s views as of the date of this release, and Verastem does not undertake and specifically disclaims any obligation to update any forward-looking statements.

Verastem, Inc.
Brian Sullivan, 781-292-4214
Director, Corporate Development
bsullivan@verastem.com

$DRWI Receives Positive NASDAQ Listing Determination

OTTAWA, CANADA–(June 7, 2017) – DragonWave Inc. (TSX:DRWI)(NASDAQ:DRWI) a leading global supplier of packet microwave radio systems for mobile and access networks, today announced that on June 6, 2017, the Company was notified that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for continued listing on Nasdaq.

The Company’s continued listing on Nasdaq is subject to the Company’s achievement of certain interim milestones, and ultimately its compliance with the $2.5 million stockholders’ equity requirement by no later than October 17, 2017. The Company is diligently working to timely satisfy the terms of the Panel’s decision.

Trading of the Company’s securities under the symbol “DRWI” on the Toronto Stock Exchange, the Company’s primary listing will not be impacted by this decision.

About DragonWave

DragonWave® is a leading provider of high-capacity packet microwave solutions that drive next-generation IP networks. DragonWave’s carrier-grade point-to-point packet microwave systems transmit broadband voice, video and data, enabling service providers, government agencies, enterprises and other organizations to meet their increasing bandwidth requirements rapidly and affordably. The principal application of DragonWave’s portfolio is wireless network backhaul, including a range of products ideally suited to support the emergence of underlying small cell networks. Additional solutions include leased line replacement, last mile fiber extension and enterprise networks. DragonWave’s corporate headquarters is located in Ottawa, Ontario, with sales locations in Europe, Asia, the Middle East and North America. For more information, visit http://www.dragonwaveinc.com.

Forward-Looking Statements

Certain statements in this release constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements regarding DragonWave’s intent to present a plan for compliance, as well as growth opportunities and the potential benefits of, and demand for, DragonWave’s products. These statements are subject to certain assumptions, risks and uncertainties, including our view of the relative position of DragonWave’s products compared to competitive offerings in the industry. Readers are cautioned not to place undue reliance on such statements. DragonWave’s actual results, performance, achievements and developments may differ materially from the results, performance, achievements or developments expressed or implied by such statements. Risk factors that may cause the actual results, performance, achievements or developments of DragonWave to differ materially from the results, performance, achievements or developments expressed or implied by such statements can be found in the public documents filed by DragonWave with U.S. and Canadian securities regulatory authorities. DragonWave assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Media Contact:
Nadine Kittle
Marketing Communications
DragonWave Inc.
nkittle@dragonwaveinc.com
+1-613-599-9991 ext 2262

Investor Contact:
Patrick Houston
CFO
DragonWave Inc.
investor@dragonwaveinc.com
+1-613-599-9991

$WINS Nasdaq Halts Wins Finance Holdings Inc.

NEW YORK, June 07, 2017  — The Nasdaq Stock Market^® (Nasdaq:NDAQ) announced that trading was halted today in Wins Finance Holdings Inc. (Nasdaq:WINS) at 12:53:20 Eastern Time for “additional information requested” from the company at a last sale price of $205.01.

Trading will remain halted until Wins Finance Holdings Inc. has fully satisfied Nasdaq’s request for additional information.

For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotes^SM on the Nasdaq^® Web site.

For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.

NDAQO

Nasdaq Media Contact:
Emily Pan
(646) 441-5120
emily.pan@nasdaq.com

$XXII Produces Non-GMO Very Low Nicotine Tobacco

22nd Century Group, Inc. (NYSE MKT:XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that the Company’s research collaboration with North Carolina State University has yielded several new Very Low Nicotine (VLN) tobacco varieties that contain no foreign DNA and no trace of genetic modification. The new Very Low Nicotine varieties are ideally suited for use in the Company’s X-22 smoking cessation product in development and will also form the basis of other unique 22nd Century VLN products.

In the United States, federal regulation will not treat the new Very Low Nicotine tobacco varieties as “genetically modified;” further, these new proprietary tobacco strains will not be subject to burdensome regulation and import restrictions in most countries around the world. Representing a major improvement on the Company’s already successful Very Low Nicotine tobacco, the new proprietary varieties hold immense promise to open up large international markets for the Company. 22nd Century is already in contact with marketers and distributors in countries with GMO restrictions (Japan, India, and Korea) to facilitate the import of products based on the Company’s new non-GMO Very Low Nicotine tobaccos.

These second generation non-GMO VLN tobacco varieties also show improved ripening and curing qualities. 22nd Century’s new non-GMO Very Low Nicotine tobaccos not only lack foreign DNA, but they are also based on superior foundational varieties. One of 22nd Century’s new non-GMO lines is based on a flue cured variety known for its superior growing characteristics and curability, while another of the Company’s non-GMO lines is based on one of the most widely grown air-cured burley tobaccos that has excellent disease resistance and yield potential. These new non-GMO Very Low Nicotine tobacco varieties are already under cultivation and study in the Company’s laboratories in Buffalo, New York. 22nd Century anticipates having commercial quantities of seed for the non-GMO varieties by 2018.

The non-GMO Very Low Nicotine tobacco varieties are protected by numerous patents under 22nd Century’s extensive patent portfolio. The Company’s patents also protect additional second generation varieties that are currently in development for the Company at North Carolina State University and in 22nd Century’s own laboratories.

“We are absolutely delighted that we have achieved our goal of producing non-GMO Very Low Nicotine tobacco,” explained Dr. Paul Rushton, 22nd Century’s Vice President for Plant Biotechnology. “Because our new non-GMO varieties contain no foreign DNA, these proprietary varieties will open up huge new markets around the world. What’s more, 22nd Century’s second-generation non-GMO VLN tobacco varieties produce an even higher quality tobacco that will further improve our Very Low Nicotine finished products.”

Professor Ralph Dewey, the Principal Investigator at North Carolina State University, stated, “We are extremely pleased that our project with 22nd Century has been such a success. These exciting new varieties will create important new Very Low Nicotine tobacco products that will avoid the GMO label. We are also pleased that our projects with 22nd Century are ongoing and that we very well may produce exciting additional VLN varieties in the coming months.”

About 22nd Century Group, Inc.

22nd Century is a plant biotechnology company focused on technology which allows it to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in cannabis plants through genetic engineering and plant breeding. The Company’s primary mission in tobacco is to reduce the harm caused by smoking. The Company’s primary mission in cannabis is to develop proprietary cannabis strains for important new medicines and agricultural crops. Visit www.xxiicentury.com and www.botanicalgenetics.com for more information.

Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release, including but not limited to our future revenue expectations. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2016, filed on March 8, 2017, including the section entitled “Risk Factors,” and our other reports filed with the U.S. Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.

$GIII to Host Earnings Call on June 6

$DRAM Provides 2016 Keystone Update on Encouraging Exploration Results

Data Suggests Large Gold-Bearing Mineral System with Potential for High-Quality Carlin-Type Gold Deposits

ELKO, Nev., June 06, 2017 — US Gold Corp. (NASDAQ:DRAM) today is pleased to provide an overall background update on our Keystone property acquisition and 2016 field exploration update.

The initial 284 mining lode claims group comprising the Keystone project was 100 percent acquired by US Gold Acquisition Corp. in late May 2016. This acquisition triggered the immediate formation of an exploration group, headed by Dave Mathewson, to commence systematic, modern-era, district-scale exploration at Keystone. The project currently consists of 479 claims, an area of almost 15 square miles (about 39 sq km). The only costs of holding this large property position are annual BLM and county claim fees.

An initial exploration review was designed and implemented to obtain, organize, evaluate, and assimilate the very large database composed of almost all the historic data of geology, surface geochemistry, geophysics, and drilling data. Approximately 150 historic holes were drilled to an average depth of about 300 feet within the district. In short order, deficiencies in this previous work were identified and programs of detailed gravity surveying and detailed geological mapping were implemented. Large target areas prospective for potential Carlin-type deposits are beginning to emerge as a result of synthesis from the historical data and the newly obtained detailed gravity survey data and geology.

The surface geochemistry, local geophysical surveys, and most of the historical drilling going back to the 1960s appear to have been largely focused on exploring for massive sulfide within skarn and hornfels adjacent to the Walti Springs pluton. Interesting levels of gold up to the 1 ppm range were encountered near and within the skarn by Newmont in the 1960s; this was the first important recognition of the presence of gold in the district. The outer, epithermal portions of the project area, where Carlin-type deposits are potentially more likely to exist, have been either very sparsely drilled, or not drilled at all.

A thorough review of all the available data, in addition to some historical holes that included economically significant gold, strongly suggested that Keystone comprised a very large gold-bearing mineral system. US Gold Corp.’s assessment further indicated that this opportunity had potential for high-quality Carlin-type gold deposits. The rock units appeared, now confirmed, to be very much like the same package of stratigraphy and lithologic rock types as is present as host rocks in the Pipeline, Cortez Hills, Goldrush, etc., of the Cortez district within the apparently same northwest-trending Cortez-Keystone structural corridor.

Further initial ground examinations indicated that Keystone is also an early Tertiary (one date of 34.1+/- 0.7 ma, K-Ar date-based) complex intrusive system. Additional field reconnaissance quickly identified several additional textural and composition plug and dikes, indicating the presence of a complex, likely long-lived, late-Eocene intrusive event and associated mineral system. Permissive host rocks comprised of the Devonian calcareous siltstone Horse Canyon and varietal Wenban limestones, and also permissive-looking Roberts Mountain limestones are exposed at the surface in a broad domal uplift (window) of the prospective host units. Broad areas of non-permissive upper plate mapped as Vinini cover much of the outer portions of the district. The geological specifics of the upper-plate rock units that have been thrust over (Roberts Mountain thrust) and broadly cover much of the permissive and prospective lower-plate rocks are being better defined by ongoing geological mapping in the district.

Detailed geological mapping of the entire district began in early July 2016 and is led by Thomas Chapin, a very experienced senior-level geologist with several years of experience in the Cortez Trend. Mr. Chapin is providing a map at detailed outcrop-scale with focus on the stratigraphy, structure, and alteration important to Carlin-type deposits; this style of mapping appears to have never been conducted in the district, and certainly not on a broad, contextual, district-wide basis. Mr. Chapin’s initial geological assessment indicates strong geological and alteration similarities to Barrick’s Cortez district to the northwest.

A five-scout hole, vertical core hole program was launched starting in the early fall of 2016 and continued to mid-December 2016 completion. This drill program hedged toward providing critical target development information in several areas of interest, especially in the almost completely undrilled eastern portion of the project area where much of the strongest surface sample geochemistry of gold, arsenic, thallium, antimony, and zinc is present in historic soil and rock samples. A sixth hole of this initial program remained undrilled in 2016, as a result of the late permitting and loss of access due to winter conditions.

Further evaluation of all the data is ongoing.  Most recently it was determined that a strong, large chargeability anomaly in a gradient Array IP survey, perhaps indicating the presence of massive sulfide in skarn, north of the Walti intrusive, was never tested by drilling.

US Gold Corp. Vice President and Head of Nevada Exploration Dave Mathewson stated, “Our 2016 Keystone Field Exploration Program served to rapidly advance some important understandings of this complex Keystone district. The core drilling in particular provided valuable information on the potential host rock lithological characteristics and stratigraphic relations. Perhaps most important was the intersection of, and recognition of thick intervals of altered, dissolution-induced collapse breccia in three of the five very widely spaced holes. Anomalous gold with up to moderately to strongly anomalous pathfinder metal geochemistry also characterized these breccia zones. One of these holes, Key16-01c, also intersected nine individual, thin, intermediate composition sills within a thick, altered collapse breccia zone believed to be within Devonian Wenban limestone.”

About US Gold Corp.
US Gold Corp is a publicly traded U.S. focused gold exploration and development company.  US Gold Corp has a portfolio of development and exploration properties.  Copper King is located in South East Wyoming and has a historical Preliminary Economic Assessment (PEA) done by Mine Development Associates in 2012 for Strathmore Minerals Corporation.  Keystone is an exploration property on the Cortez trend in Nevada, identified and consolidated by Dave Mathewson.  For more information about US Gold Corp, please visit www.usgoldcorp.gold

Dataram is an independent manufacturer of memory products and provider of performance solutions that increase the performance and extend the useful life of servers, workstations, desktops and laptops sold by leading manufacturers such as Dell, Cisco, Fujitsu, HP, IBM, Lenovo and Oracle. Dataram’s memory products and solutions are sold worldwide to OEMs, distributors, value-added resellers and end users. Additionally, Dataram manufactures and markets a line of Intel Approved memory products for sale to manufacturers and assemblers of embedded and original equipment. 70 Fortune 100 companies are powered by Dataram. Founded in 1967, the Company is a US based manufacturer, with presence in the United States, Europe and Asia. For more information about Dataram, visit www.dataram.com.

Safe Harbor
The information provided in this press release may include forward-looking statements relating to future events, such as the exploration success of US Gold Corp, development of new Dataram products, pricing and availability of raw materials or the future financial performance of the Company.  Actual results may differ from such projections and are subject to certain risks including, without limitation, risks arising from: changes in the price of gold and mining industry cost inputs, memory chips, changes in the demand for memory systems, increased competition in the memory systems industry, order cancellations, delays in developing and commercializing new products, risks with respect to US Gold Corp faced by junior companies generally engaged in exploration activities, and other factors described in the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including  the Risk Factors with respect to U.S. Gold contained in the Current Report on Form 8-K filed on June 13, 2016, filed with the Securities and Exchange Commission, which can be reviewed at www.sec.gov.  The Company has based these forward-looking statements on its current expectations and assumptions about future events.  While management considers these expectations and assumptions to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory, and other risks, contingencies, and uncertainties, most of which are difficult to predict and many of which are beyond the Company’s control.  The Company does not assume any obligations to update any of these forward-looking statements.

For additional information, please contact:

US Gold Corp Investor Relations Contact:
+1 800 557 4550
ir@usgoldcorp.gold
www.usgoldcorp.gold

$EGLT Announces ARYMO® ER Added to Large Payer Formulary

WAYNE, Pa., June 6, 2017 — Egalet Corporation (Nasdaq: EGLT) (“Egalet”), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced one of the largest payers in the United States will provide coverage of ARYMO^® ER (morphine sulfate) extended-release tablets, for oral use –CII.

“Obtaining coverage of ARYMO ER for over 24 million member lives is an important step in the early phase of our launch and removes a barrier to access to healthcare providers and the patients they treat,” said Patrick Shea, chief commercial officer of Egalet. “With over 98% of the extended-release (ER) morphine products on the market in easy to abuse forms, ARYMO ER, an abuse-deterrent, ER morphine product, is an important treatment option for those living with chronic pain and to help deter potential abuse.”

Please see important safety information on ARYMO ER, including boxed warning and medication guide, below.  Abuse of ARYMO ER by injection, as well as by the oral and nasal routes, is still possible.

The new formulary drug coverage is effective immediately. Under the agreement, OXAYDO^® (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX^® (ketorolac tromethamine) Nasal Spray also are covered through 2018.

About Egalet
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has three approved products: ARYMO^® ER (morphine sulfate) extended-release tablets for oral use –CII, developed using Egalet’s proprietary Guardian™ Technology, OXAYDO^® (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX^® (ketorolac tromethamine) Nasal Spray. Using Guardian Technology, Egalet is developing a pipeline of clinical-stage, product candidates including Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. For full prescribing information on ARYMO ER, including the boxed warning and medication guide, please visit arymoer.com. For full prescribing information on SPRIX, including the boxed warning and medication guide, please visit sprix.com. For full prescribing information on OXAYDO, including the boxed warning and medication guide, please visit oxaydo.com. For additional information about Egalet, please visit egalet.com.

IMPORTANT SAFETY INFORMATION ABOUT ARYMO ER

Indications

ARYMO ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Limitations of Use

• Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve ARYMO ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
• ARYMO ER is not indicated as an as-needed (prn) analgesic.

Contraindications

ARYMO ER is contraindicated in patients with:  significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment; concurrent use of monoamine oxidase inhibitors (MAOIs) or use within the last 14 days, known or suspected gastrointestinal obstruction, including paralytic ileus; hypersensitivity (e.g., anaphylaxis) to morphine.

Warnings and Precautions

Addiction, Abuse, and Misuse: ARYMO ER contains morphine, a Schedule II controlled substance. As an opioid, ARYMO ER exposes its users to the risks of addiction, abuse, and misuse. As extended-release products such as ARYMO ER deliver the opioid over an extended period of time, there is a greater risk for overdose and death due to the larger amount of morphine present.

Life-Threatening Respiratory Depression: Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient’s clinical status. Carbon dioxide (CO₂) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.

While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of ARYMO ER, the risk is greatest during the initiation of therapy or following a dosage increase. Monitor patients closely for respiratory depression, especially within the first 24-72 hours of initiating therapy with and following dosage increases with ARYMO ER.

To reduce the risk of respiratory depression, proper dosing and titration of ARYMO ER are essential. Overestimating the ARYMO ER dose when converting patients from another opioid product can result in a fatal overdose with the first dose.

Accidental ingestion of even one dose of ARYMO ER, especially by children, can result in respiratory depression and death due to an overdose of morphine.

Neonatal Opioid Withdrawal Syndrome: Prolonged use of ARYMO ER during pregnancy can result in withdrawal in the neonate. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly. Advise pregnant women using opioids for a prolonged period of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Risks from Concomitant Use with Benzodiazepines or Other CNS Depressants: Profound sedation, respiratory depression, coma, and death may result from the concomitant use of ARYMO ER with benzodiazepines or other CNS depressants (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate.

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioid analgesics alone. Because of similar pharmacological properties, it is reasonable to expect similar risk with the concomitant use of other CNS depressant drugs with opioid analgesics.

Life-Threatening Respiratory Depression in Patients with Chronic Pulmonary Disease or in Elderly, Cachectic, or Debilitated Patients: The use of ARYMO ER in patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment is contraindicated.

Patients with Chronic Pulmonary Disease: ARYMO ER-treated patients with significant chronic obstructive pulmonary disease or cor pulmonale, and those with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages of ARYMO ER.

Elderly, Cachectic, or Debilitated Patients: Life-threatening respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance compared to younger, healthier patients.

Monitor such patients closely, particularly when initiating and titrating ARYMO ER and when ARYMO ER is given concomitantly with other drugs that depress respiration. Alternatively, consider the use of non-opioid analgesics in these patients.

Interaction with Monoamine Oxidase Inhibitors: Monoamine oxidase inhibitors (MAOIs) may potentiate the effects of morphine, including respiratory depression, coma, and confusion. ARYMO ER should not be used in patients taking MAOIs or within 14 days of stopping such treatment.

Adrenal Insufficiency: Cases of adrenal insufficiency have been reported with opioid use, more often following greater than one month of use. Presentation of adrenal insufficiency may include non-specific symptoms and signs including nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure.

Severe Hypotension: ARYMO ER may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is an increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics). Monitor these patients for signs of hypotension after initiating or titrating the dose of ARYMO ER. In patients with circulatory shock, ARYMO ER may cause vasodilation that can further reduce cardiac output and blood pressure. Avoid the use ARYMO ER in patients with circulatory shock.

Risks of Use in Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness: In patients who may be susceptible to the intracranial effects of CO₂ retention (e.g., those with evidence of increased intracranial pressure or brain tumors), ARYMO ER may reduce respiratory drive, and the resultant CO₂ retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy with ARYMO ER.

Opioids may also obscure the clinical course in a patient with a head injury. Avoid the use of ARYMO ER in patients with impaired consciousness or coma.

Difficulty in Swallowing and Risk for Obstruction in Patients at Risk for a Small Gastrointestinal Lumen: Moistened ARYMO ER tablets may become sticky leading to difficulty in swallowing the tablets. Patients could experience choking, gagging, regurgitation and tablets stuck in the throat. Instruct patients not to pre-soak, lick, or otherwise wet ARYMO ER tablets prior to placing in the mouth, and to take one tablet at a time with enough water to ensure complete swallowing immediately after placing in the mouth.

Tablet stickiness and swelling may also predispose patients to intestinal obstruction and exacerbation of diverticulitis. Patients with underlying GI disorders such as esophageal cancer or colon cancer with a small gastrointestinal lumen are at greater risk of developing these complications. Consider use of an alternative analgesic in patients who have difficulty swallowing and patients at risk for underlying GI disorders resulting in a small gastrointestinal lumen.

Risks of Use in Patients with Gastrointestinal Conditions: ARYMO ER is contraindicated in patients with gastrointestinal obstruction, including paralytic ileus. The morphine in ARYMO ER may cause spasm of the sphincter of Oddi. Opioids may cause increases in the serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.

Increased Risk of Seizures in Patients with Seizure Disorders: The morphine in ARYMO ER may increase the frequency of seizures in patients with seizure disorders, and may increase the risk of seizures occurring in other clinical settings associated with seizures. Monitor patients with a history of seizure disorders for worsened seizure control during ARYMO ER therapy.

Withdrawal: Avoid the use of mixed agonist/antagonist (i.e., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who have received or are receiving a course of therapy with a full opioid agonist analgesic, including ARYMO ER. In these patients, mixed agonists/antagonist and partial agonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.

When discontinuing ARYMO ER, gradually taper the dose. Do not abruptly discontinue ARYMO ER.

Risks of Driving and Operating Machinery: ARYMO ER may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of ARYMO ER and know how they will react to the medication.

Adverse Reactions

In clinical trials, the most common adverse reactions with morphine sulfate extended-release formulations were constipation, dizziness, sedation, nausea, vomiting, sweating, dysphoria, and euphoric mood.

Additional Drug Interactions

Serotonergic Drugs: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome.

Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: May reduce the analgesic effect of ARYMO ER and/or precipitate withdrawal symptoms; avoid concomitant use.

Muscle Relaxants: Morphine may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.

Cimetidine: The concomitant use of cimetidine can potentiate morphine effects and increase risk of hypotension, respiratory depression, profound sedation, coma, and death.

Diuretics: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.

Anticholinergic Drugs: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.

P-Glycoprotein (P-gp) Inhibitors: The concomitant use of P-gp inhibitors can increase the exposure to morphine by about two-fold and can increase risk of hypotension, respiratory depression, profound sedation, coma, and death.

Use in Specific Populations

Pediatrics: The safety and effectiveness in pediatric patients below the age of 18 have not been established.

Geriatrics: The pharmacokinetics of ARYMO ER have not been studied in elderly patients. Elderly patients (aged 65 years or older) may have increased sensitivity to morphine.

Hepatic Impairment: Morphine pharmacokinetics have been reported to be significantly altered in patients with cirrhosis. Start these patients with a lower than usual dosage of ARYMO ER and titrate slowly while monitoring for signs of respiratory depression, sedation, and hypotension.

Renal Impairment: Morphine pharmacokinetics are altered in patients with renal failure. Start these patients with a lower than usual dosage of ARYMO ER and titrate slowly while monitoring for signs of respiratory depression, sedation, and hypotension.

Overdosage

Acute overdosage with morphine can be manifested by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and, in some cases, pulmonary edema, bradycardia, hypotension, partial or complete airway obstruction, atypical snoring, and death. Marked mydriasis rather than miosis may be seen due to severe hypoxia in overdose situations.

Safe Harbor
Statements included in this press release (including but not limited to upcoming milestones) that are not historical in nature and contain the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “look forward to” and other similar expressions are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the success of Egalet’s clinical trials, including the timely recruitment of trial subjects and meeting the timelines therefor; Egalet’s ability to obtain regulatory approval of Egalet’s product candidates and the labeling claims that Egalet believes are necessary or desirable for successful commercialization of its products and product candidates; Egalet’s ability to maintain the intellectual property position of Egalet’s products and product candidates; Egalet’s ability to identify and reliance upon qualified third parties to manufacture its products; Egalet’s ability to commercialize its products, and to do so successfully; the costs of commercialization activities, including marketing, sales and distribution; the size and growth potential of the markets for Egalet’s products and product candidates, and Egalet’s ability to service those markets; Egalet’s ability to obtain reimbursement and third-party payor contracts for its products; Egalet’s ability to service its debt obligations; Egalet’s ability to raise additional funds to execute its business plan and growth strategy on terms acceptable to Egalet, if at all; Egalet’s ability to find and hire qualified sales professionals; the rate and degree of receptivity in the marketplace and among physicians to Egalet’s products; the success of products that compete with Egalet’s that are or become available; general market conditions; and other risk factors set forth in Egalet’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the United States Securities and Exchange Commission (SEC) and in other filings Egalet makes with the SEC from time to time. While Egalet may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.

Media and Investor Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: bcs@egalet.com
Tel: 484-259-7370

$AMRS Announces Reverse Stock Split

EMERYVILLE, Calif., June 06, 2017  — Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced that it will effect a reverse stock split previously approved by the company’s stockholders at its annual meeting on May 23, 2017. As a result of the reverse stock split, every 15 pre-split shares of common stock held by stockholders will automatically be converted into one share of common stock. The reverse stock split became effective as of the close of business on June 5, 2017 and the company’s common stock will begin trading on a split-adjusted basis as of the commencement of trading today. The number of shares of the company’s authorized common stock was also reduced from 500,000,000 to 250,000,000 shares.

Immediately following the reverse stock split, Amyris’s common stock will continue to trade on the NASDAQ Global Select Market under the symbol “AMRS”. The new CUSIP number for the common stock following the reverse stock split will be 03236M200. The reverse stock split is intended to increase the market price per share of the company’s common stock to allow the company to maintain the listing of its common stock on The NASDAQ Global Select Market.

“With $86 million of debt retired and our financing needs largely behind us, we are now very focused on continuing to execute on our strategy,” said John Melo, Amyris President & CEO. “We are delivering significant disruption for our partners in cosmetic skin care, vitamins and flavors and fragrances and we are on track to more than double our product revenue this year to over $60 million and continuing delivery on our stable $50-60 million of annual collaboration revenue. Upon the expected close of the second tranche of financing, we believe we are done with major fund raising and are excited about our focus on making the planet healthier and helping our partners become more sustainable.”

Upon the effectiveness of the reverse stock split, each 15 shares of the company’s issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock, par value $0.0001 per share. The company will not issue any fractional shares in connection with the reverse stock split. Instead, fractional share interests will be rounded up to the nearest whole share. Proportional adjustments will be made to the conversion and exercise prices of the company’s outstanding warrants, convertible notes and stock options, and the number of shares issued and issuable under the company’s equity compensation plans. The reverse stock split will not modify the rights or preferences of the common stock.

Shareholders with shares held in book-entry form or through a bank, broker, or other nominee are not required to take any action and will see the impact of the reverse stock split automatically reflected in their accounts following the customary procedures followed by the bank, broker, or other nominee in regard to the reverse stock split. Shareholders with shares held in certificate form will receive instructions from the exchange agent for the reverse stock split, Wells Fargo Shareowner Services, for exchanging their stock certificates for a new certificate representing the shares of common stock resulting from the reverse split. Wells Fargo Shareowner Services can be reached at 1-800-401-1957.

Additional information about the reverse stock split can be found in the company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 27, 2017, a copy of which is available at www.sec.gov or by visiting the investor relations section of the company’s website at www.amyris.com.

About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.

Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the anticipated effects of the reverse stock split, including on the market price per share of the company’s common stock, the expected maintaining of the listing of the company’s common stock on The NASDAQ Global Select Market, anticipated future financing activity, and expected product and collaboration revenue) that involve risks and uncertainties. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s quarterly report on Form 10-Q filed on May 15, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris, the Amyris logo and No Compromise are registered trademarks of Amyris, Inc.

Contact:

Peter DeNardo
Director, Investor Relations and Corporate Communications
Amyris, Inc. 
+1 (510) 740-7481
investor@amyris.com
pr@amyris.com

$CIIX Engages Launch Haus to Drive its Hemp-based eCommerce

SAN GABRIEL, California, June 6, 2017 —

ChineseInvestors.com, Inc. (OTCQB: CIIX) (“CIIX” or “the Company”), the premier financial information website for Chinese-speaking investors, today announces that it has formally engaged Launch Haus, LLC (“Launch Haus”), venture building firm and digital holding company, based in Scottsdale, AZ, specializing in direct response marketing including digital, ecommerce, and direct sales channels. Launch Haus will play an integral part in directing the Company’s organization and launch of its direct-to-consumer ecommerce and network marketing business divisions.

Launch Haus has a strong presence in the direct-selling industry and its principals have a proven track record having built sales organizations with an excess of $1.5 billion in commissionable volume over the last 10 years.

“We are very excited to work with ChineseInvestors.com, Inc. on its new campaign and believe that the Company can successfully implement its unique, customer-centric business model which aims to provide health conscious consumers with amazing hemp-based products and an equally amazing international business opportunity,” said Chris J. Snook, Managing Partner at Launch Haus, LLC and author of Digital Sense (Wiley, 2017).

Following the Company’s impressive third quarter financial reports, CIIX believes that it is on track to announce an official launch date of its direct selling platform in the coming fiscal year.

“Launch Haus is the perfect firm to oversee CIIX’s direct response marketing campaign which will include significant direct-to-consumer ecommerce channels such as Amazon and development of the Company’s international network marketing platform as we begin to drive revenues in the coming fiscal year. We are prepared for rapid domestic and international expansion,” said Warren Wang CEO of CIIX.

Highlights of the engagement:

In addition to general go-to-market planning and customer experience consulting, Launch Haus has been engaged to:

• Develop a customized cutting-edge direct response marketing campaign that will focus on personalized, customer-centric marketing and sales force automation.
• Develop a compensation plan that incentivizes both rapid growth through recruitment of new, entry-level consumers and top-tier distributors.
• Introduce CIIX to its stable of industry-leading suppliers for global payment systems and logistics and its network of distributor recruitment and legal governance and compliance professionals.

In recognition of the unprecedented opportunities in the legal hemp industry, CIIX is expanding its business to capitalize on the growing demand for hemp-based health products via online retail and direct sales channels.

Meanwhile, CIIX also maintains its commitment to continue to grow its membership subscriptions and investor relations business.

About ChineseInvestors.com (CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational-related services in Chinese language character sets (traditional and simplified); (b) advertising and public relations related support services; and (c) retail, online and direct sales of hemp-based products and other health-related products. For more information visit http://www.ChineseInvestors.com.

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom and https://www.facebook.com/Chineseinvestors.com.english

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776

Investor Relations:
Alan Klitenic
+1.214.636.2548

Corporate Communications:
NetworkNewsWire (NNW)
New York, New York
http://www.NetworkNewsWire.com
+1.212.418.1217 Office
Editor@NetworkNewsWire.com

$ACOR CVT-301 Phase 3 Data Significantly Improved Motor Function, Parkinson’s

Acorda Therapeutics, Inc. (Nasdaq:ACOR) presented data from its Phase 3 SPAN-PD clinical trial of CVT-301 (levodopa inhalation powder) that showed a statistically significant, clinically meaningful improvement in motor function, as measured by the Unified Parkinson’s Disease Rating Scale – Part III (UPDRS III) in people with Parkinson’s experiencing OFF periods. Multiple secondary endpoints, including achievement of an ON state with maintenance through 60 minutes and Patient Global Impression of Change (PGIC), were supportive of the primary endpoint result. These findings are being presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS), being held in Vancouver, British Columbia from June 4-8, 2017.

Acorda is developing CVT-301 as a treatment for symptoms of OFF periods in people with Parkinson’s taking a carbidopa / levodopa regimen. OFF periods refer to the re-emergence of Parkinson’s symptoms.

Key Efficacy and Safety Findings: Phase 3 SPAN-PD Study

The poster “Inhaled levodopa (CVT-301, 84-mg dose) significantly improves motor function during OFF periods in Parkinson’s disease subjects: A Phase 3 Study (SPAN-PD)” (Poster #LBA34) highlighted findings from a 12-week, placebo-controlled trial that enrolled 339 participants.

The study met its primary endpoint, with CVT-301 84 mg showing statistically significant improvement in motor function compared to placebo as measured by mean change in the UPDRS III at 30-minutes post-dose at Week 12 (-9.83 vs. -5.91; p = 0.009).

Secondary efficacy analyses were performed using a pre-specified hierarchy. The order of hierarchy was set based on probability of success, guided by the Phase 2b results. The primary endpoint (CVT-301 84 mg vs. placebo) was tested first for statistical significance. Upon achieving significance, the secondary endpoints were tested for CVT-301 84 mg vs. placebo followed by CVT-301 60 mg in the hierarchical order, as long as each preceding endpoint reached a significance level of P < 0.05. The hierarchical sequence did not reach statistical significance at Step 3. Unadjusted (nominal) p-values are presented below for all key secondary endpoints.

The most commonly reported adverse events in the CVT-301 84 mg group compared to the placebo group were: cough (14.9% vs. 1.8%, reported mostly once/subject), upper respiratory tract infection (6.1% vs. 2.7%), nausea (5.3% vs. 2.7%), sputum discoloration (5.3% vs. 0%) and dyskinesia (3.5% vs. 0.0%). When cough was reported, it was typically characterized as mild. Two of 114 participants receiving CVT-301 84 mg discontinued the study due to cough.

Key Safety and Exploratory Efficacy Findings: Long-Term Safety Study

In addition to the data presented at the MDS congress, Acorda announced interim data from an ongoing long-term safety study (CVT-301-005). This is a 52-week open-label study comparing treatment with CVT-301 84 mg with an observational control group. Participants were randomized in a 2:1 ratio into either the CVT-301 84 mg arm (n=271) or the observational control arm (n=127) of the study.

The primary objective of this study is to assess pulmonary function. Measures include Forced Expiratory Volume in 1 second (FEV1) and diffusing capacity of the lung for carbon monoxide (DLco).

There were no statistical differences in the mean changes in FEV1 and DLco from baseline to Week 52 between the CVT-301 84 mg and observational control groups.

The most common adverse events that were reported in any study arm at >5% were:

All reported fractures were judged by the investigators to be unlikely related or not related to study drug. Most reports of cough were mild (91%), none was severe. Three of 271 participants (1.1%) receiving CVT-301 discontinued the study due to cough.

Participants reporting serious adverse events (SAEs) were as follows: 13 (10.2%) in the observational control arm and 40 (14.8%) in the CVT-301 84 mg arm. Urinary tract infection occurred in four participants (1.5%) receiving CVT-301 84 mg. No other SAEs in the CVT-301 treatment group were reported at greater than 1%. There was one death in the study, a drowning in the CVT-301 84 mg group, judged by the investigator to be not related to study drug.

The study also included several uncontrolled, exploratory efficacy measurements that were only conducted in the CVT-301 arm of the study. Exploratory endpoints are hypothesis-generating. Findings included:

• At Week 52, the least-square mean of UPDRS III change from pre-dose at 30 minutes post-dose was -15.13 (n=130).
• 85% of participants (n=129) maintained an ON state 60 minutes post-dose at Week 52.
• 73% of participants (n=165) reported improvement as measured by PGIC at Week 52.
• The least-square mean reduction in daily OFF time among participants who completed the Week 52 visit (n=108) was 1.15 hours.
• Over the course of the study, the average daily usage of CVT-301 was 2.3 doses per day.

Acorda plans to file an NDA for CVT-301 with the U.S. Food and Drug Administration (FDA) by the end of the second quarter of 2017, and a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) by the end of the year.

Investor Webcast Information

The Company will host a webcast for investors to provide an overview of the CVT-301 clinical program on June 5, 2017 at 4:30 pm Eastern / 1:30 pm Pacific. This will include data being presented at the MDS Congress, as well as additional interim findings from a long-term safety study.

The webcast will include presentations by Matthew Stern, M.D., University of Pennsylvania, Peter LeWitt, M.D., Wayne State University School of Medicine, and Donald Grosset, M.D., Institute of Neurological Sciences, Queen Elizabeth University Hospital (Glasgow).

The webcast will be available on the Investor Events page of www.acorda.com and will be archived in the same location for replay. To participate via conference call, please dial 800-806-5484 (U.S.) or 416-340-2217 (international) and reference the access code 8170198#. An audio replay will be available until June 12, 2017 at 1:00 pm Eastern at 800-408-3053 (U.S.) or 905-694-9451 (international) using access code 5949682#.

About Parkinson’s disease and OFF Periods

Approximately one million people in the U.S. and 1.2 million Europeans are diagnosed with Parkinson’s disease (PD); OFF periods are experienced by approximately 350,000 in the U.S. and 420,000 in Europe.

Parkinson’s is a progressive neurodegenerative disorder resulting from the gradual loss of certain neurons responsible for producing dopamine. It causes a range of symptoms including impaired movement, muscle stiffness and tremors. As PD progresses, people with Parkinson’s experience OFF periods, which are characterized by the re-emergence of PD symptoms. This re-emergence can occur even when an individual’s treatment regimen has been optimized.

OFF periods can be very disruptive to the lives of people with Parkinson’s, their families and caregivers. OFF periods can increase in frequency and severity during the course of the disease.

About CVT-301 (levodopa inhalation powder) and ARCUS^®

CVT-301 is a self-administered, inhaled levodopa (L-dopa) therapy in development for the treatment of symptoms of OFF periods in people with Parkinson’s disease taking a carbidopa / levodopa regimen.

CVT-301 utilizes Acorda’s investigational ARCUS^® platform for inhaled therapeutics. CVT-301 was designed to deliver a precise dose of a dry powder formulation of L-dopa to the lung. Oral medication can be associated with variable onset of action, as the medicine is absorbed through the gastrointestinal (digestive) tract before reaching the brain. Inhaled treatments enter the body through the lungs and reach the brain, bypassing the digestive system.

About Acorda Therapeutics

Founded in 1995, Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA^® (dalfampridine) Extended Release Tablets, 10 mg. For more information, please visit the Company’s website at: www.acorda.com.

Forward-Looking Statement

This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management’s expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including: the ability to realize the benefits anticipated from the Biotie and Civitas transactions, among other reasons because acquired development programs are generally subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired programs generally improves over time; the ability to successfully integrate Biotie’s operations and Civitas’ operations, respectively, into our operations; we may need to raise additional funds to finance our expanded operations and may not be able to do so on acceptable terms; our ability to successfully market and sell Ampyra (dalfampridine) Extended Release Tablets, 10 mg in the U.S., which will likely be materially adversely affected by the recently announced court decision in our litigation against filers of Abbreviated New Drug Applications (each, an “ANDA”) to market generic versions of Ampyra in the U.S.; third party payers (including governmental agencies) may not reimburse for the use of Ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other research and development programs, including INBRIJA (CVT-301, levodopa inhalation powder), or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market INBRIJA, any other products under development, or the products that we acquired with the Biotie transaction; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain and maintain regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaborator Biogen in connection therewith; competition; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action by regulatory agencies.

These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this press release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

$SPCB 42% Revenue Growth In First Quarter 2017

HERZLIYA, Israel, June 5, 2017  — SuperCom (NASDAQ: SPCB), a global provider of secure solutions for the e-Government, Public Safety, HealthCare, and Finance sectors, announced results for the first quarter ended March 31, 2017.

First Quarter 2017 Financial Highlights As Compared to First Quarter 2016

• Revenue of $8.3 million compared to $5.9 million, an increase of 42%
• Gross Margin of 36.5% compared to 14.7%, an increase of 150%
• Non-GAAP Gross Margin of 39.2% compared to 17.7%
• EBITDA loss totaled ($0.76 million) compared to ($0.95) million
• Non-GAAP Net Loss of ($0.9 million) compared to ($1.2 million)
• Non-GAAP EPS of $(0.07) compared to ($0.08)
• R&D operating expenses of $1.7 million compared to $1.2 million

Arie Trabelsi, SuperCom’s President and CEO commented, “During the first quarter, our dramatically improved results reflect the financial benefits we are beginning to realize from our strengthened business model.  2016 was a transformational year with four acquisitions that leveraged SuperCom’s DNA of serving the chief security officer of a nation or enterprise and positioned us as a global provider of e-government and security solutions across several high growth markets including national identity, electronic monitoring, cyber security and secure connectivity. These markets have high barriers to entry and a broader base of predictable recurring revenues.  As we move through 2017, we will continue to drive our shift to more recurring revenue from a more diverse customer base to support our long term growth.  We remain comfortable with our previously stated expectation that the percentage of our steady-state revenues from developed markets will grow from less than 5% in 2015 to close to 50% in 2017.  As our customer base evolves from primarily government entities to now include top corporations from the banking, telecom, finance and retail industries, among others, we are lessening our exposure to the volatility we experienced with our previous concentration in national governments in emerging markets.”

Mr. Trabelsi continued, “We have focused considerable attention on driving efficiencies in our business and drove margin improvement across our business, especially when comparing our results to the back half of 2016.  Gross margins more than doubled over the same quarter last year.  Furthermore, we reduced our operating costs as we realized synergies in our business, positioning us favorably to drive enhanced profitability as we grow revenue.”

Mr. Trabelsi concluded, “While we are pleased to have demonstrated progress in the first quarter of 2017, there is a great deal of work ahead.  We are increasingly confident about our revenue pipeline, contiue to drive integration, and are confident that we will continue to realize improved financial performance as we move through 2017.”

First Quarter 2017 Highlights by Segment: 

e-ID:

• $9M Secure Web Land Geographical Information System project in Colombia, on track for deployment completion and transition to steady-state in July 2018.
• March 2017: Awarded $3 million contract to provide various core elements of our flexible electronic-ID solutions.

M2M:

• March 2017: Awarded an EM contract in Ontario, Canada valued at up to $1.7 million in revenues.
• March 2017: Selected by the Czech Republic’s Ministry of Justice, for a $3.7 million national EM project.

Cyber Security:

• Achieved quarterly sales growth as recognizable revenues move closer to bookings, with deferred revenues approaching further stability.

Connectivity and Payments

• Launched a Mobile e-Wallet Solution with VeriFone and Nofshonit for one of Israel’s largest loyalty clubs with over one million active clients

Financial Outlook

Based on the current information available to the Company, management re-affirms its belief that revenue for the full year 2017 will surpass $35 million, an approximately 75% increase compared to 2016.

Results Conference Call

The Company will host a conference call, today, Monday, June 5, 2017, at 10 a.m. Eastern time to review the Company’s first quarter financial results and business outlook.

To participate, interested investors should call one of the following telephone numbers. It is recommended that participants dial in at least five minutes before the start of the call:

A webcast of the call will be available on the SuperCom investor relations website at http://www.supercom.com.

About SuperCom

Since 1988, SuperCom has been a leading global provider of traditional and digital identity solutions, providing advanced safety, identification and security solutions to governments and organizations, both private and public, throughout the world. Through its proprietary e-Government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance and border control services, SuperCom has inspired governments and national agencies to design and issue secure

Multi-ID documents and robust digital identity solutions to its citizens and visitors. SuperCom offers a unique all-in-one field-proven RFID & mobile technology and product suite, accompanied by advanced complementary services for various industries including healthcare and homecare, security and safety, community public safety, law enforcement, electronic monitoring, livestock monitoring, and building and access automation.

SuperCom’s website is http://www.supercom.com

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded or followed by or that otherwise include the words “believes”, “expects”, “anticipates”, “intends”, “projects”, “estimates”, “plans”, and similar expressions or future or conditional verbs such as “will”, “should”, “would”, “may” and “could” are generally forward-looking in nature and not historical facts. Forward-looking statements in this release also include statements about business and economic trends. Investors should also consider the areas of risk described under the heading “Forward Looking Statements” and those factors captioned as “Risk Factors” in the Company’s periodic reports under the Securities Exchange Act of 1934, as amended, or in connection with any forward-looking statements that may be made by the Company. These statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on May 16, 2016. The Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

Use of Non-GAAP Financial Information

In addition to disclosing financial results calculated in accordance with United States generally accepted accounting principles (GAAP), this release of operating results also contains non-GAAP financial measures, which SuperCom believes are the principal indicators of the operating and financial performance of its business. Management believes the non-GAAP financial measures provided are useful to investors’ understanding and assessment of the Company’s on-going core operations and prospects for the future, as the charges eliminated are not part of the day-to-day business or reflective of the core operational activities of the Company.  Management uses these non-GAAP financial measures as a basis for strategic decisions, forecasting future results and evaluating the Company’s current performance.  However, such measures should not be considered in isolation or as substitutes for results prepared in accordance with GAAP.  Reconciliation of the non-GAAP measures to the most comparable GAAP measures are provided in the schedules attached to this release.

[Tables follow]

Company Contact:

Ordan Trabelsi, President Americas

Tel: 1 212 675 4606

ordan@supercom.com

$PXS Complimentary Transcript Available for Product Tanker Webinar

With the CEOs of Concordia Maritime, d’Amico International Shipping and Pyxis Tankers

CONTACT
For further information please contact:
Nicolas Bornozis
Capital Link, Inc.
Tel. (212) 661-7566
Email: shipping@capitallink.com

$COVS Definitive Agreement to be Acquired by $OTEX

DETROIT, June 05, 2017  — Covisint Corporation (NASDAQ:COVS) the leading Cloud Platform for building Identity and Internet of Things (IoT) applications, today announced that it has entered into a definitive agreement to be acquired by OpenText™ (NASDAQ:OTEX) (TSX:OTEX), the global leader in Enterprise Information Management (EIM).

Under the terms of the agreement, OpenText will acquire all outstanding shares of Covisint common stock in a transaction valued at approximately $103 million.  Covisint shareholders will receive $2.45 per share in cash for each outstanding share of common stock held.  This transaction is compelling for Covisint shareholders, offering immediate liquidity at a substantial premium.  The $2.45 per share consideration represents a 23% premium to the prior closing price on June 2, 2017, a 27% premium to the 30-day volume-weighted average price, and a 46% cash-adjusted premium⁽¹⁾ to the 30-day volume weighted average price.

“After a comprehensive review of strategic options by our Board of Directors, we are very pleased to have reached an agreement with OpenText.  We believe this all-cash transaction offers Covisint shareholders immediate liquidity and substantial certainty of value, and represents the best path forward for all of Covisint’s stakeholders,” said Sam Inman, Covisint’s CEO.  “This acquisition is a strong recognition of Covisint’s leadership in Identity and IoT platforms.  We are pleased that our process concluded with OpenText as our partner, and we believe they will add significant value and expertise to accelerate our growth.  There is no better place for the Covisint Platform, the Covisint team members and our customers at this time in our evolution.”

The transaction has been unanimously approved by the Board of Directors of Covisint and is expected to close in the third quarter of calendar 2017.  Consummation of the transaction is subject to customary closing conditions, including approval by holders of Covisint’s common stock.

Evercore is serving as financial advisor to Covisint and Paul Hastings LLP is acting as legal counsel.

About Covisint Corporation

Covisint is the connected company – we securely connect ecosystems of people, systems and things to enable new service offerings, optimize operations, develop new business models and ultimately enable the connected economy.  Today, we support more than 2,000 organizations and connect to more than 212,000 business partners and customers worldwide.  Learn more at www.covisint.com.

Follow us:

• Covisint on Twitter
• Covisint on LinkedIn
• Covisint on Facebook

(1) The cash-adjusted calculation deducts the Company’s cash and cash equivalents of $33 million or $0.79 per share as of March 31, 2017 from both its current share price and from the total Merger Consideration implied by the offer in order to better reflect the premium being offered.

About OpenText
OpenText enables the digital world, creating a better way for organizations to work with information, on premises or in the cloud.  For more information about OpenText (NASDAQ:OTEX) (TSX:OTEX) visit opentext.com.

Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements about the expected timing, completion and effects of the proposed transaction and all other statements in this communication, other than historical facts.  Any forward-looking statements contained in this press release are based upon Covisint’s historical performance and its current plans, estimates and expectations and are not a representation that such plans, estimates, or expectations will be achieved.  These forward-looking statements represent Covisint’s expectations as of the date of this press release.  Subsequent events may cause these expectations to change, and Covisint disclaims any obligation to update the forward-looking statements in the future except as may otherwise be required by the federal securities laws.  These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, for example, Covisint may not be able to complete the proposed transaction on the terms described herein or other acceptable terms or at all.  Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, (2) the failure to obtain the requisite approval of Covisint’s shareholders or the failure to satisfy other closing conditions, (3) risks related to disruption of management’s attention from Covisint’s on-going business operations due to the pending transaction and, (4) the effect of the announcement of the pending transaction on the ability of Covisint to retain and hire key personnel, maintain relationships with its customers and suppliers, and maintain its operating results and business generally.  Further information on potential factors that could affect actual results is included in Covisint’s reports filed with the SEC.

Investor Relations Contact
866.319.7659  
investors@covisint.com

Media Contacts
Jeannette Bitz, Witz Communications (for Covisint)
510.599.5499
jbitz@witzcommunications.com

For Sales and Marketing Information
Covisint Corporation, 26533 Evergreen Road, Suite 500, Southfield, MI 48076, 800-229-4125
http://www.covisint.com

$CLSN Presentation of OVATION Study Findings at the ASCO 2017

100% disease control rate and 86% objective response rate reported

All patients at the highest dose demonstrated an objective response rate – partial (80%) or complete (20%) response rate

At the highest dose, 100% of patients achieved a R0, margin-negative, resection

LAWRENCEVILLE, N.J., June 05, 2017 — Celsion Corporation (NASDAQ:CLSN), an oncology drug development company, today provided an update on its OVATION Study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company’s DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced (stage III/IV) ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery.  GEN-1 is an IL-12 DNA plasmid vector formulated as a nanoparticle in a non-viral delivery system to cause the sustained local production and secretion of the Interleukin-12 (IL-12) protein loco-regionally at the tumor site.   

The Company announced the latest clinical and translational data from the OVATION Study in a poster presentation at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting at McCormick Place in Chicago, IL.  The poster presentation, entitled “Phase 1 study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer,” was presented on Saturday, June 3rd from 1:15 PM to 4:45 PM by Dr. Premal H. Thaker, Associate Professor, Obstetrics and Gynecology Division of Gynecologic Oncology, Washington University in St. Louis School of Medicine.  The presentation summarized clinical findings and available translational data from all fourteen patients treated in the trial to-date.

“The OVATION study has accrued patients from four major research cancer centers.  We have seen highly promising clinical findings including a patient with a complete pathological response along with a very high rate of R0 at time of debulking surgery.  The translational research data in the poster presentation demonstrates that GEN-1 is producing beneficial cytokines and positively impacting T-cells in the tumor,” said Dr. Premal Thaker. “This is strong early data and we believe that GEN-1 may be stimulating the immune system to improve tumor control in these patients. I am looking forward to continuing our clinical evaluation of GEN-1 in subsequent ovarian cancer studies.”

Celsion reported encouraging clinical data from the first fourteen patients who have completed treatment in the OVATION Study.  GEN-1 plus standard chemotherapy produced positive results, with no dose limiting toxicities and promising dose dependent efficacy signals which appear to correlate well with successful surgical outcomes as summarized below:

• Of the fourteen patients treated to date in the entire study, two (2) patients demonstrated a complete response, ten (10) patients demonstrated a partial response and two (2) patients demonstrated stable disease, as measured by RECIST criteria. This translates to a 100% disease control rate (“DCR”) and an 86% objective response rate (“ORR”).  Of the five patients treated in the highest dose cohort, there was a 100% objective response rate with one (1) complete response and four (4) partial responses.
• Fourteen patients had successful resections of their tumors, with nine (9) patients (64%) having an R0 resection, which indicates a microscopically margin-negative resection in which no gross or microscopic tumor remains in the tumor bed.  Of the five patients treated at the highest dose cohort, all five patients (100%) experienced a R0 surgical resection.
• One patient demonstrated a pathological complete response (pCR). pCRs are typically seen in less than 7% of patients receiving neoadjuvant chemotherapy followed by surgical resection, and have been associated with a median overall survival (OS) of 72 months, which is more than three years longer than those who do not experience a pCR.
• All patients experienced a clinically significant decrease in their CA-125 protein levels as of their most recent study visit. CA-125 is used to monitor certain cancers during and after treatment. CA-125 is present in greater concentrations in ovarian cancer cells than in other cells.

Celsion also reported supportive translational research data from the first four patient cohorts who have completed treatment in the OVATION Study.  The translational data provides further insight into GEN-1’s mechanism of action through the evaluation of dose-related changes in the tumor and peritoneal immune cell population, as well as through the peritoneal cytokine levels.

Treatment-Related Changes in IL-12 and Cytokine Levels in Peritoneal Fluid

• The analysis of peritoneal fluid and blood samples collected immediately before and 24 hours after IP administration of multiple doses of GEN-1 (36, 47, 61, 79 mg/m2) and standard NACT (carboplatin every 21 days and Taxol weekly) shows clear evidence of IL-12 gene transfer and biological response following GEN-1 treatment on a dose-dependent basis.
• The translational data also demonstrated significant increases in IFN-gamma and decreases in VEGF levels.  The treatment-related changes in immune activating cytokines and pro-tumor VEGF levels followed a dose-dependent trend and were predominantly in the peritoneal fluid compartment with little to no changes observed in the patients’ systemic blood stream.

Treatment-Related Changes in the Density of Various T-cells in Tumors

• The immuno-histochemical (IHC) analysis of tumor tissue collected before treatment (laparoscopy) and after completion of eight GEN-1 weekly treatments showed increased infiltration of CD3+, CD4+ CD8+ T-cells into tumor tissue of several patients.  The most pronounced effects observed in the IHC analysis were decreases in the density of immunosuppressive T-cell signals (FoxP3+, PD-1+, PDL-1+, IDO-1+) in the tumor microenvironment.  The ratio of CD8+ cells to immunosuppressive T-cells was increased in 60-80% of patients suggesting an overall shift in the immune environment to pro-immune stimulatory following treatment with GEN-1.
• An intriguing effect of the treatment on tumor microenvironment is a substantial reduction in the immunosuppressive T-cell subsets and an overall shift in the T-cell environment to favoring immune stimulation.

“Now having completed enrollment, per protocol, of our OVATION Study, we are impressed with GEN-1’s apparent activity in combination with standard chemotherapy in newly diagnosed patients with stage III and IV ovarian cancer.  These data appear to correlate with the notable, unexpected surgical outcomes among all patients completing the prescribed eight weekly treatments and reinforce our confidence in the promise of GEN-1’s ability to work safely and effectively in advanced ovarian cancer,” said Michael H. Tardugno, Celsion’s chairman, president and CEO. “Given these encouraging findings, in addition to our plans to evaluate GEN-1 in combination with Avastin® in 2^nd line, the Company will consider continuing our clinical trials in the underserved newly diagnosed patient population.”

OVATION Study Design

The Phase Ib trial evaluated weekly intraperitoneal dosing of GEN-1 in combination with neoadjuvant chemotherapy, the standard of care for patients newly diagnosed with ovarian cancer. Concurrently with neoadjuvant chemotherapy, enrolled patients received escalating weekly doses of GEN-1, from levels beginning at 36mg/m², to 47mg/m², 61mg/m² and 79mg/m² weekly for 8 treatments in total, followed by interval debulking surgery. The regimen is primarily being evaluated for its safety and tolerability.

About GEN-1 Immunotherapy

GEN-1, designed using Celsion’s proprietary TheraPlas platform technology, is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anti-cancer immunity acting through the induction of T-lymphocyte and natural killer (NK) cell proliferation. The Company has previously reported positive safety and encouraging Phase I results with GEN-1 given as monotherapy in patients with peritoneally metastasized ovarian cancer, and recently completed a Phase Ib trial of GEN-1 in combination with PEGylated doxorubicin in patients with platinum-resistant ovarian cancer.

About Celsion Corporation

Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company’s lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in Phase II development for the treatment of recurrent chest wall breast cancer.  The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers.  Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: http://www.celsion.com. (CLSN-G1 CLSN-OV)

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995.  Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim OVATION Study clinical data, particularly in small subgroups that are not statistically significant; FDA and regulatory uncertainties and risks; the significant expense, time, and risk of failure of conducting clinical trials, particularly for Phase I trials such as the OVATION Study; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Celsion’s periodic reports and prospectuses filed with the Securities and Exchange Commission.  Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Celsion Investor Contact

Jeffrey W. Church
Sr. Vice President and CFO
609-482-2455
jchurch@celsion.com

$NK to Present at the Jefferies Healthcare Conference on June 7, 2017

NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7^th, in New York City at 8:30 a.m. ET.

In conjunction with this conference, Patrick Soon-Shiong, M.D., Chairman and CEO of NantKwest, will be participating in a panel discussion titled, “Adoption of Emerging Genomics Tools for Oncology in Clinical Diagnostics.” The panel discussion is scheduled for Wednesday, June 7, 2017, beginning at 9 a.m. ET.

An audio only webcast of the presentation will be available at www.nantkwest.com. Listeners are encouraged to visit the web site at least 10 minutes prior to the start of the presentation to register, download and install any necessary software. The presentation will be archived and accessible on the web site for at least 90 days.

About NantKwest Inc.

NantKwest (Nasdaq:NK) is a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory diseases. NK cells are the body’s first line of defense due to the innate ability of NK cells to rapidly identify and destroy cells under stress, such as cancer or virally-infected cells.

NantKwest’s unique NK cell-based platform, with the capacity to grow active killer cells as a biological cancer therapy, has been designed to induce cell death against cancer or infected cells by three different modes of action: (1) Direct killing using activated NK cells (aNK) that release toxic granules directly into the cell through cell to cell contact, (2) Antibody-mediated killing using haNKs, which are NK cells engineered to incorporate a high affinity receptor that binds to an administered antibody, enhancing the cancer cell killing effect of that antibody, and (3) Targeted activated killing using taNKs, which are NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells.

Our aNK, haNK and taNK platform addresses certain limitations of T cell therapies including the reduction of risk of serious “cytokine storms” reported after T cell therapy. As an “off-the-shelf” therapy, NantKwest’s NK cells do not rely on a patient’s own often compromised immune system. In Phase 1 clinical trials in patients with late stage cancer, NantKwest’s NK cells have been successfully administered as an outpatient infusion therapy without any reported severe side effects, even at doses of 10 billion cells.

By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs that include a Phase 2 trial for a rare form of melanoma and the planned initiation of a clinical trial of NK cells targeted to breast cancer, we believe NantKwest is uniquely positioned to be the premier immunotherapy company and transform medicine by delivering living drugs in a bag and bringing novel NK cell-based therapies to routine clinical care. For more information please visit www.nantkwest.com.

$BYSI to Present at the Jefferies 2017 Healthcare Conference

NEW YORK, June 02, 2017 — BeyondSpring Inc. (NASDAQ:BYSI), a late-stage clinical development company focused on a rich pipeline of innovative immuno-oncology cancer therapies, announced today that Dr. Lan Huang, Ph.D., Chairman and CEO, will present at the Jefferies 2017 Healthcare Conference on Thursday, June 8, 2017 at 8:00 a.m. Eastern Time.

A live webcast of the conference call will be available online which can be accessed through the Investors section of BeyondSpring’s website, http://ir.beyondspringpharma.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. An archived replay of the webcast will be available on the Company’s website after the conference.

Management will also be available for one-on-one meetings at the Conference. Investors attending the conference who wish to meet with management for a one-on-one meeting should notify their appropriate contact or e-mail healthcareconference@jefferies.com.

About BeyondSpring
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and Phase 2/3 clinical trials in the prevention of chemotherapy-induced neutropenia. BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.

About Plinabulin
Studies on Plinabulin’s method of action indicate that Plinabulin activates GEF-H1, a guanine nucleotide exchange factor. GEF-H1 activates downstream transduction pathways leading to the activation of the protein c-Jun. Activated c-Jun enters the nucleus of dendritic cells to up-regulate immune-related genes, which contributes to the up-regulation of a series of genes leading to dendritic cell maturation, T-cell activation and other effects that prevent neutropenia.

Investor Relations: 
Garth Russell / Steve Silver
KCSA Strategic Communications
P: +1-212-682-6300
grussell@kcsa.com / ssilver@kcsa.com

Media Relations:
Caitlin Kasunich / Amy Singh
KCSA Strategic Communications
212.896.1241 / 212.896.1207
ckasunich@kcsa.com / asingh@kcsa.com

$CTHR Collaborates with American Gem Society on Moissanite Education

Charles & Colvard, Ltd. (NASDAQ: CTHR), the original and leading worldwide source of created moissanite, today announced its collaboration with the American Gem Society (AGS) to raise awareness for moissanite. For the first time, the American Gem Society now recognizes moissanite on its website https://www.americangemsociety.org/en/moissanite.

The American Gem Society is the leading organization helping protect the jewelry-buying public from fraud and false advertising. Since 1934, they have dedicated themselves to consumer protection, ethical business practices and the development and maintenance of superior gemological skills and knowledge.

Moissanite is a lab-created, eco-friendly gemstone that competes with diamond for share of wallet. Its high quality and unique chemical structure elicits unrivaled fire and brilliance. With a refractive index of 2.65-2.69, it exhibits more brilliance than diamond and is among the hardest minerals on the earth with a 9.25 on the MOHs hardness scale. Moissanite is a new approach to jewelry for a new century.

Due to a growing demand for lab-created, ethically sourced gemstones, moissanite is increasingly becoming an option for the socially conscious, value-driven consumer. “We are pleased to recognize moissanite on our website and diversify our gemstone portfolio. We will also be publishing an article on moissanite in our consumer enews Brilliance in an upcoming issue, as well several features in our social media. Our goal is to be a resource for consumers on gemstones, and information on moissanite plays an important role in that mix,” said Katherine Bodoh, CEO of the American Gem Society and AGS Laboratories.

“We’ve been members of AGS for 17 years and are excited to continue our longstanding relationship with the organization. Their role in protecting and educating consumers is critical to helping consumers distinguish moissanite from other clear gemstones such as diamond, white sapphire and cubic zirconia,” said Charles & Colvard President and CEO Suzanne Miglucci. “In adding moissanite to their website, AGS is addressing a market need for more information on lab-created gemstones for consumers thinking beyond traditional choices.”

Forever One is the epitome of created moissanite. It’s a socially responsible, luxurious fine jewelry option for the consumer who is thinking beyond traditional choices. To find a local jeweler selling Charles & Colvard Created Moissanite, visit where to buy. For wholesale purchases, please see our list of authorized distributors.

For more information on Charles & Colvard Created Moissanite, please visit www.charlesandcolvard.com.

About Charles & Colvard, Ltd.

Charles & Colvard, Ltd., based in the Research Triangle Park area of North Carolina, is the original creator and leading source of Forever One™, Forever Brilliant® and Forever Classic™ moissanite gemstones for fine jewelry. Moissanite is unique, available in three color grades (colorless, near-colorless and faint color) and produced from silicon carbide (SiC) crystals. Charles & Colvard Created Moissanite® is sold with a Limited Lifetime Warranty to wholesale distributors, manufacturers, retailers, TV shopping networks, and designers as loose stones or set in a wide variety of quality metal setting options. Charles & Colvard, Ltd. also sells direct to consumers through its wholly owned operating subsidiary, charlesandcolvard.com, LLC and through third-party marketplaces. Charles & Colvard, Ltd.’s common stock is listed on the NASDAQ Global Select Market under the symbol “CTHR.” For more information, please visit www.charlesandcolvard.com.

$TGTX Recaps Schedule of Clinical Data Presentations

Positive results from the GENUINE Phase 3 study to be featured in an oral presentation

NEW YORK, June 02, 2017 — TG Therapeutics, Inc. (NASDAQ:TGTX) today recapped the schedule of presentations featuring TG-1101 and TGR-1202 at the upcoming 53^rd Annual Meeting of the American Society of Clinical Oncology (ASCO), being held this week, June 2 – 6, 2017, at McCormick Place in Chicago, Illinois.

Oral Presentation:

• Title: Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study
  – Abstract Number: 7504
  – Date & Time: Saturday, June 3, 2017 3:00 PM – 6:00 PM CT
  – Presentation Time: 4:12 PM CT
  – Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
  – Presenter: Jeffrey P. Sharman, MD

Poster Discussion Presentation:

• Title: Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL
  – Abstract Number: 7511
  – Presentation Date & Time: Monday, June 5, 2017 8:00 AM-11:30 AM CT (Poster Viewing); 1:15 PM-2:30 PM CT (Poster Discussion)
  – Session Title: Poster Discussion Session, Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
  – Presenter: Loretta Nastoupil, MD

Trials in Progress Poster Presentation:

• Title: KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy
  – Abstract Number: TPS7569
  – Presentation Date & Time: Monday, June 5, 2017 8:00 AM-11:30 AM CT
  – Session Title: Poster Session, Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
  – Presenter: Colleen Dorsey, BSN, RN

Abstracts are available online and can be accessed at www.asco.org. Following each presentation, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com.

TG THERAPEUTICS INVESTOR & ANALYST EVENT

TG Therapeutics will host a reception on Monday, June 5, 2017 beginning at 7:00pm CT, with featured presentations now beginning promptly at 7:05pm CT.  The event will take place at the Peninsula Chicago Hotel in the Avenues Ballroom.  This event will be webcast live and will be available on the Events page, located within the Investors & Media section of the Company’s website at www.tgtherapeutics.com, as well as archived for future review.   This event will also be broadcast via conference call.  To access the conference line, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), and reference Conference Title: TG Therapeutics June 2017 Investor & Analyst Event.

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies, with TG-1101 also in clinical development for autoimmune disorders. The Company also has pre-clinical programs to develop IRAK4 inhibitors, BET inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties.  For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  In addition to the risk factors identified from time to time in our reports filed with the Securities and Exchange Commission, factors that could cause our actual results to differ materially are the following: our ability to successfully and cost effectively complete preclinical and clinical trials; the risk that early clinical trial results, that may have supported the acceptance of our data for presentation or influenced our decision to proceed with additional clinical trials, will not be reproduced in future studies or in the final presentations; the risk that the combination of TG-1101 and TGR-1202, referred to as TG-1303 and being studied in the UNITY clinical trials, will not prove to be a safe and efficacious combination or backbone for triple and/or quad therapies; the risk that any interim analyses from ongoing clinical trials will not produce the desired or predicted result. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

TGTX – G

CONTACT:

Jenna Bosco
Vice President- Investor Relations
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: ir@tgtxinc.com

$DVAX Updated Data for SD-101 in Combination with KEYTRUDA

Data Presented at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

$LLEX Announces Flow Rates on the Hippo #1H

THE HIPPO #1H RECENT 24-HR RATE OF 1,917 BOEPD, 4,105 FT LATERAL

SAN ANTONIO, June 1, 2017  — Lilis Energy, Inc. (NYSE MKT: LLEX), an exploration and development company operating in the Permian Basin of West Texas, today announced that the Hippo #1H reached a peak 24hr rate on May 26, 2017 of 1,917 Boepd at 4,105 lateral feet on a three-stream basis, or 1,662 Boepd on a two-stream basis. The well currently is producing at 67% oil; 74% liquids on a three-stream basis.

The Hippo #1H has been online for 46 days and is producing on a restricted choke with more than 1,600 pounds of flowing tubing pressure. The Hippo #1H’s 4,105-foot lateral well was completed with 20 stages of 200-foot plug to plug spacing with approximately 2,200 lbs. of sand per foot. The Hippo #1H has not yet reached a peak 30-day initial production rate.

“The Hippo is our third successful operated horizontal Wolfcamp B well this year, all with IP rates exceeding initial internal projections,” said Avi Mirman, Lilis’s Chief Executive Officer.

About Lilis Energy, Inc.

Lilis Energy, Inc. is a San Antonio-based independent oil and gas exploration and production company that operates in the Permian’s Delaware Basin, considered amongst the leading resource plays in North America. Lilis’s total net acreage in the Permian Basin is over 10,000 acres. Lilis Energy’s near-term E&P focus is to grow current reserves and production and pursue strategic acquisitions in its core areas. For more information, please visit www.lilisenergy.com.

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the federal securities laws. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. These risks include, but are not limited to our ability to replicate the results described in this release for future wells; the ability to finance our continued exploration, drilling operations and working capital needs, all the other uncertainties, costs and risks involved in exploration and development activities; and the other risks identified in the Company’s Annual Report on Form 10-K and its other filings with the Securities and Exchange Commission (the “SEC”). Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in the forward-looking statements. The forward-looking statements in this press release are made as of the date hereof, and the Company does not undertake any obligation to update the forward-looking statements as a result of new information, future events or otherwise.

$CBMG Announces Stock Repurchase Program

SHANGHAI, China and CUPERTINO, Calif., June 01, 2017 — Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the Company’s Board of Directors (the “Board”) has approved a new stock repurchase program granting the company authority to repurchase up to $10 million in common shares (the “2017 Stock Repurchase Program”) through open market purchases pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and in accordance with Rule 10b-18 of the Exchange Act.  Under the new stock repurchase program, which is designed to return value to CBMG’s stockholders, the company plans to repurchase shares in the open market in accordance with all applicable securities laws and regulations, including Rule 10b-18 of the Securities Exchange Act of 1934, as amended.

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards.  CBMG recently commenced two Phase I human clinical trials in China using CAR-T to treat Refractory Diffuse Large B-cell Lymphoma (DLBCL), a Phase I human clinical trial to treat relapsed/refractory CD19+ B-cell Acute Lymphoblastic Leukemia (ALL), as well as an ongoing Phase I trial in China for AlloJoin^TM (CBMG’s “Off-the-Shelf” Allogeneic Human Adipose-derived Mesenchymal Stem Cell) for the treatment of Knee Osteoarthritis (KOA). CBMG was recently awarded $2.29 million from the California Institute for Regenerative Medicine (CIRM) to support pre-clinical studies of AlloJoin^TM for Knee Osteoarthritis in the United States. The Company also recently announced a strategic partnership with GE Healthcare Life Sciences China to establish a joint technology laboratory to develop control processes for the manufacture of CAR-T and stem cell therapies. To learn more about CBMG, please visit www.cellbiomedgroup.com.

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy, including the devaluation of the RMB by China in August 2015 and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Contacts:
Sarah Kelly 
Director of Corporate Communications, CBMG
+1 408-973-7884
sarah.kelly@cellbiomedgroup.com

$XBIT Phase III Findings for its Antibody Therapy for Colorectal Cancer

Data Show Reduced Disease Progression and Improved Survival for Patients Achieving Primary Endpoint 

AUSTIN, Texas, June 01, 2017 – XBiotech Inc. (NASDAQ:XBIT) announced today that data from XBiotech’s European Phase III Study of advanced colorectal cancer patients treated with Hutruo (MABp1) will be presented at the 2017 American Society of Clinical Oncology (ASCO) meeting in Chicago, Illinois. The abstract entitled, “MABp1 improves clinical outcomes of patients with symptomatic refractory metastatic colorectal cancer patients: Per-Protocol Population analysis of Phase III Study (PT026)” will be presented during the Gastrointestinal Colorectal Cancer poster session on June 3, 2017 from 8am-11:30am. Dr. Lucjan Wyrwicz from the Maria Sklodowska-Curie Memorial Cancer Centre, Institute of Oncology, Warsaw, will be leading the poster session.

The poster will provide analysis of how patients performed during and after treatment with the prescribed 8 week treatment regimen. Patients that received the full 8 weeks of treatment are considered to have completed the study “per protocol” (i.e. did not leave the study early). Assessment of the treatment outcome for the per protocol group is particularly important, since due to the advanced stage of these patients, some are unable to complete the recommended treatment regimen and are not able to have the full potential benefit from therapy.

In the Phase III study, 82% of all patients that received at least one dose of study drug did complete the 8 week treatment regimen. For these per protocol patients, 40% of patients that received treatment with the antibody therapy achieved the primary endpoint, nearly double compared to placebo (40% vs 23%, relative risk 1.76, 95% CI 1.14 to 2.72, one-tailed p=0.003). Dr. Wyrwicz is providing an analysis showing how patients in this population that achieved the primary endpoint of the study had substantially improved survival outcomes, with a median survival of 11.7 months versus 5.7 months for those that did not (HR 0.39; p<0.0001). Other key findings include RECIST assessment of tumor progression, where radiographic evidence of stable disease was more than three-fold better (42% vs 12%; p<0.001) in this population.

Dr. Wyrwicz commented, “This analysis confirms our previous report that in an advanced cancer population, the combination of patient-reported symptoms and radiography used as the primary endpoint is a powerful measure of disease progression.” He further stated, “These findings show that the use of this endpoint to measure disease modifying anti-tumor therapies is a logical surrogate to assess new anti-cancer agents in chemorefractory patients.”

About True Human(TM) Therapeutic Antibodies
XBiotech’s True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech’s True Human antibodies have the potential to harness the body’s natural immunity to fight disease with increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human(TM) proprietary technology. XBiotech currently is advancing a robust pipeline of antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management’s beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “would,” “could,” “expects,” “plans,” “contemplate,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “intend” or “continue” or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the “Risk Factors” section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930

$SPI Announces Receipt of Minimum Bid Price Notice From NASDAQ

HONG KONG, June 01, 2017  — SPI Energy Co., Ltd. (“SPI Energy” or the “Company”) (Nasdaq:SPI), a global clean energy market place for business, residential, government and utility customers and investors, today announced that it received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (“Nasdaq”) on May 25, 2017 notifying the Company that the minimum bid price per American depositary share (“ADS”), each representing ten ordinary shares of the Company, was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Rule 5450(a)(1) of the Nasdaq Listing Rules. The Nasdaq notification letter does not result in the immediate delisting of the Company’s securities.

Pursuant to Rule 5810(c)(3)(A) of the Nasdaq Listing Rules, the Company has a compliance period of 180 calendar days, or until November 21, 2017 (the “Compliance Period”), to regain compliance with Nasdaq’s minimum bid price requirement. If at any time during the Compliance Period, the closing bid price per ADS is at least $1.00 for a minimum of 10 consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed.

In the event that the Company does not regain compliance by November 21, 2017, the Company may transfer to the Nasdaq Capital Market where, subject to the determination by the staff of Nasdaq, it may be eligible for an additional 180 calendar day compliance period if it meets the initial listing requirements, with the exception of bid price, of the Nasdaq Capital Market, and provides written notice to Nasdaq of its intention to cure the deficiency.

About SPI Energy Co., Ltd.

SPI Energy Co., Ltd. is a global provider of photovoltaic (PV) solutions for business, residential, government and utility customers and investors. SPI Energy focuses on the EPC/BT, storage and O2O PV market including the development, financing, installation, operation and sale of utility-scale and residential PV projects in China, Japan, Europe and North America. The Company operates an innovative online energy e-commerce and investment platform, www.solarbao.com, which enables individual and institutional investors to purchase innovative PV-based investment and other products; as well as www.solartao.com, a B2B e-commerce platform offering a range of PV products for both upstream and downstream suppliers and customers. The Company has its operating headquarters in Hong Kong and maintains global operations in Asia, Europe, North America and Australia. For additional information, please visit: www.spisolar.com.

For investors and media inquiries please contact:

SPI Energy Co., Ltd.
IR Department
Email: ir@spisolar.com

$CCIH Receives CDN License from the Chinese Government

BEIJING, June 01, 2017  — ChinaCache International Holdings Ltd. (“ChinaCache” or the “Company”) (Nasdaq:CCIH), a leading total solutions provider of Internet content and application delivery services in China, today announced that it has received the “Content Delivery Network (CDN) Business Operating License” from the Ministry of Industry and Information Technology of the People’s Republic of China.

Under the terms of the license, the Company is allowed to operate four types of Type I valued-added telecom businesses including (1) CDN business in all parts of China, (2) Internet Data Center (IDC) business in four municipalities directly under the authority of the central government and in fourteen other cities, (3) VPN business in two municipalities directly under the authority of the central government and six other cities, and (4) Internet connection business in four municipalities directly under the authority of the central government and in thirteen provinces.

Mr. Song Wang, Chairman and CEO of CCIH commented, “We are pleased to receive the new CDN license that covers both the CDN and the IDC businesses and provides us with a distinct competitive advantage as we further deliver customized total solution services to our customers. We received the first CDN license in China from the Chinese government in 2002 and the new license reaffirms the quality of our service and technology. Starting January 1, 2018, companies without CDN licenses will be prohibited from providing CDN services in China.”

About ChinaCache International Holdings Ltd.

ChinaCache International Holdings Ltd. (Nasdaq:CCIH) is a leading total solutions provider of Internet content and application delivery services in China. As a carrier-neutral service provider, ChinaCache’s network in China is interconnected with networks operated by all telecom carriers, major non-carriers and local Internet service providers. With more than a decade of experience in developing solutions tailored to China’s complex Internet infrastructure, ChinaCache is a partner of choice for businesses, government agencies and other enterprises to enhance the reliability and scalability of online services and applications and improve end-user experience. For more information on ChinaCache, please visit ir.chinacache.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. ChinaCache may also make written or oral forward-looking statements in its reports filed or furnished to the U.S. Securities and Exchange Commission, in its annual reports to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statements, including but not limited to the following: the Company’s goals and strategies, expansion plans, the expected growth of the content and application delivery services market, the Company’s expectations regarding keeping and strengthening its relationships with its customers, and the general economic and business conditions in the regions where the Company provides its solutions and services. Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and ChinaCache undertakes no duty to update such information, except as required under applicable law.

For investor and media inquiries please contact:

Investor Relations Department
ChinaCache International Holdings
Tel: +86 10 6408 5307
Email: ir@chinacache.com

Mr. Ross Warner
The Piacente Group | Investor Relations
Tel: +86 10 5730-6200
Email: chinacache@tpg-ir.com

Ms. Brandi Piacente
The Piacente Group | Investor Relations
Tel: +1 212-481 2050
Email: chinacache@tpg-ir.com

$CIIX to Attend 6th Annual SeeThru Equity Microcap Investor Conference

SAN GABRIEL, California, June 1, 2017  —

ChineseInvestors.com, Inc. (OTCQB: CIIX) (‘CIIX’ or the ‘Company’), the premier financial information website for Chinese-speaking investors, announces that it will attend the 6th Annual SeeThru Equity Microcap Investor Conference taking place today at 101 Park Avenue, New York, NY.

SeeThru Equity has been providing impactful, high-quality research on underfollowed small-cap and microcap equities since 2011, and the firm is well-known for its unbiased equity research. As this much anticipated event does every year, the 2017 SeeThru Equity Microcap Investor Conference will offer the exclusive opportunity for investors to discover publicly traded companies with market capitalizations less than $1 billion.

“SeeThru Equity gave CIIX a target price of $2.05 one year ago,” says Warren Wang, Founder and CEO of CIIX. He further added, “Recently, the firm increased CIIX’s price target to $3.75, reflecting huge growth potential based on our legal medical cannabis initiatives. In addition, SeeThru Equity also gave CIIX a forecast for revenue from its hemp business, projecting the revenue could grow from $0.7 million in FY2017 to reach 8-digit sales by FY2020E, with continued growth thereafter.

CIIX is in the early stages of penetrating the world’s legal medical cannabis market; however, increased market opportunity paired with our demonstrated insight of investing in the medical cannabis industry will enable the Company to capitalize on a unique approach to broad medical cannabis industry growth. We sincerely encourage you to come to our booth at the SeeThru Equity Microcap Investor Conference to learn more about CIIX and the incredible opportunities that await.”

About ChineseInvestors.com (OTCQB: CIIX)

Founded in 1999, ChineseInvestors.com endeavors to be an innovative company providing: (a) real-time market commentary, analysis, and educational related services in Chinese language character sets (traditional and simplified); (b) advertising and public relation related support services; and (c) retail and online sales of hemp-based products and other health related products.

For more information visit ChineseInvestors.com

Subscribe and watch our video commentaries: https://www.youtube.com/user/Chinesefncom

Follow us on Twitter for real-time Company updates: https://twitter.com/ChineseFNEnglsh

Like us on Facebook to receive live feeds: https://www.facebook.com/Chinesefncom

Add us on WeChat: Chinesefn or download iPhone iOS App: Chinesefn

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Contact:
ChineseInvestors.com, Inc.
227 W. Valley Blvd, #208 A
San Gabriel, CA 91776

Investor Relations:
Alan Klitenic
+1-214-636-2548

Corporate Communications:
NetworkNewsWire (NNW)
New York, New York
http://www.NetworkNewsWire.com
+1-212-418-1217 Office
Editor@NetworkNewsWire.com